U.S. patent application number 16/988316 was filed with the patent office on 2021-07-01 for small molecule activators of mitochondrial function.
This patent application is currently assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA. The applicant listed for this patent is THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA. Invention is credited to Phillip A. Benedetti, Maria Grazia Cotticelli, Donna M. Huryn, Jason E. Melvin, Amos SMITH, Robert B. WILSON.
Application Number | 20210198244 16/988316 |
Document ID | / |
Family ID | 1000005451057 |
Filed Date | 2021-07-01 |
United States Patent
Application |
20210198244 |
Kind Code |
A1 |
WILSON; Robert B. ; et
al. |
July 1, 2021 |
SMALL MOLECULE ACTIVATORS OF MITOCHONDRIAL FUNCTION
Abstract
Methods for improving mitochondrial function, decreasing iron
accumulation, and/or decreasing oxidative stress by exposing cells
or treating a subject to compounds or compositions of the general
formula ##STR00001## are described that are beneficial in treating,
for example, diseases and conditions such as Friedreich's ataxia,
normal aging, and various neurodegenerative diseases such as
Alzheimer's disease and Parkinson's disease. Furthermore, such
compounds are useful as probes for identifying defects in
mitochondrial metabolism, mitochondrial iron accumulation, cellular
stress among other mitochondrial diseases and helping to identify
compounds active in overcoming such defects.
Inventors: |
WILSON; Robert B.;
(Wynnewood, PA) ; Cotticelli; Maria Grazia;
(Philadelphia, PA) ; Benedetti; Phillip A.; (San
Francisco, CA) ; SMITH; Amos; (Merion Station,
PA) ; Melvin; Jason E.; (Philadelphia, PA) ;
Huryn; Donna M.; (Allentown, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
Philadelphia |
PA |
US |
|
|
Assignee: |
THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA
Philadelphia
PA
|
Family ID: |
1000005451057 |
Appl. No.: |
16/988316 |
Filed: |
August 7, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15613043 |
Jun 2, 2017 |
10745390 |
|
|
16988316 |
|
|
|
|
14679855 |
Apr 6, 2015 |
9695157 |
|
|
15613043 |
|
|
|
|
13139162 |
Oct 26, 2011 |
9000009 |
|
|
PCT/US2009/067517 |
Dec 10, 2009 |
|
|
|
14679855 |
|
|
|
|
61121477 |
Dec 10, 2008 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Q 1/025 20130101;
A61K 31/47 20130101; C07D 215/14 20130101; G01N 2500/10 20130101;
G01N 2333/39 20130101; C07D 405/06 20130101; C07D 409/06
20130101 |
International
Class: |
C07D 409/06 20060101
C07D409/06; A61K 31/47 20060101 A61K031/47; C07D 215/14 20060101
C07D215/14; C07D 405/06 20060101 C07D405/06; C12Q 1/02 20060101
C12Q001/02 |
Claims
1.-102. (canceled)
103. A pharmaceutical composition comprising a compound of formula
(I): ##STR00025## wherein A is an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.1 is hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.2 is hydroxy or --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and R.sup.4 and R.sup.6 are each independently
hydrogen, --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --COR.sup.7, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with an oxygen, a
--C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and R.sup.7
is hydrogen, --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
104. The pharmaceutical composition of claim 103 wherein the
compound has formula (II): ##STR00026## wherein B is O, N or S;
R.sup.1 is hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro,
NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4,
or an optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; R.sup.2 is hydroxy or
--OR, wherein R is --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--SO.sub.2NR.sup.4R.sup.6, --SO.sub.2R.sup.7, --COR.sup.7,
--COOR.sup.7 or --CONR.sup.4R.sup.6, wherein (a) one or more of the
carbon atoms in the alkyl, alkenyl or alkynyl group is each
independently optionally replaced with a nitrogen, sulfur or oxygen
atom, and (b) the alkyl, alkenyl or alkynyl group is optionally
substituted with a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano, alkyloxy,
nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4,
COOR.sup.4, optionally substituted aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aromatic, or heteroaromatic; and
R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
105. The pharmaceutical composition of claim 104 wherein R.sup.3 is
alkyl or aralkyl.
106. The pharmaceutical composition of claim 104 wherein R.sup.5 is
one or more halo, alkyl or alkoxy.
107. The pharmaceutical composition of claim 104 wherein the
compound is selected from among
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
108. The pharmaceutical composition of claim 103 wherein the
compound of formula (I) has the structure of formula (III):
##STR00027## wherein R.sup.1 is hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.2 is hydroxy or --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.4 and R.sup.6 are each independently
hydrogen, --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --COR.sup.7, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with an oxygen, a
--C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; R.sup.5 is
one or more hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro,
NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4,
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; and R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing; and a pharmaceutically acceptable carrier, recipient or
diluent.
109. The pharmaceutical composition of claim 108 wherein R.sup.3 is
alkyl or aralkyl.
110. The pharmaceutical composition of claim 108 wherein R.sup.5 is
one or more halo, alkyl or alkoxy.
111. The pharmaceutical composition of claim 8 wherein the compound
is selected from among
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
112. A compound having the structure of formula (I): ##STR00028##
wherein A is an optionally substituted aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aromatic, or heteroaromatic; R.sup.1
is hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; R.sup.2 is hydroxy or
--OR, wherein R is --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--SO.sub.2NR.sup.4R.sup.6, --SO.sub.2R.sup.7, --COR.sup.7,
--COOR.sup.7 or --CONR.sup.4R.sup.6, wherein (a) one or more of the
carbon atoms in the alkyl, alkenyl or alkynyl group is each
independently optionally replaced with a nitrogen, sulfur or oxygen
atom, and (b) the alkyl, alkenyl or alkynyl group is optionally
substituted with a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; and R.sup.4 and R.sup.6
are each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
113. The compound of claim 112 wherein R.sup.1 is halo.
114. The compound of claim 112 wherein R.sup.2 is hydroxy.
115. The compound of claim 112 wherein A is a substituted aryl
group or an optionally substituted furyl group.
116. The compound of claim 112 wherein R.sup.3 is an optionally
substituted alkyl or aralkyl group.
117. The compound of claim 112 having the structure of formula
(II): ##STR00029## wherein B is O, N or S; R.sup.1 is hydrogen,
hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4,
NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; R.sup.2 is hydroxy or --OR, wherein R
is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.4 and R.sup.6 are each independently
hydrogen, --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --COR.sup.7, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with an oxygen, a
--C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; R.sup.5 is
one or more hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro,
NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4,
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; and R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
118. The compound of claim 117 wherein R.sup.1 is hydroxy, nitro or
halogen.
119. The compound of claim 117 wherein R.sup.3 is alkyl or
aralkyl.
120. The compound of claim 117 which is
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e.
121. The compound of claim 112 having the formula (III):
##STR00030## wherein R.sup.1 is hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.2 is hydroxy or --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; R.sup.3 is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; R.sup.4 and R.sup.6 are each independently
hydrogen, --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --COR.sup.7, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with an oxygen, a
--C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; R.sup.5 is
one or more hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro,
NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4,
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; and R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
122. The compound of claim 121 wherein R.sup.1 is hydroxy, nitro or
halogen.
123. The compound of claim 121 wherein R.sup.5 is one or more
alkyl, alkoxy, dimethylamino or halogen.
124. The compound of claim 121 wherein R.sup.3 is an alkyl or
aralkyl moiety.
125. The compound of claim 121 selected from
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide, and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide.
Description
BACKGROUND OF THE INVENTION
[0001] Mitochondrial dysfunction has been established to contribute
to the pathology of numerous diseases and is suspected in many
more. A role for loss of mitochondrial function in normal aging has
long been suspected. Most hypotheses focus on free radical damage
to mitochondrial DNA. Mitochondrial DNA (mtDNA) lies in close
proximity to the mitochondrial respiratory chain, which produces
free radicals even during normal respiration. Somatic mtDNA
mutations accumulate with age in post-mitotic tissues in
association with a decline in mitochondrial function. MtDNA
mutations are propagated during the turnover of mitochondria, which
have a limited lifespan of only a few weeks, even in post-mitotic
cells. Because mtDNA contributes disproportionally to respiratory
complexes I, III, and IV, these complexes are disproportionally
affected when mtDNA is damaged. Disproportional effects on
mitochondrial respiratory complexes increase the production of free
radicals by impeding the normal flux of electrons through the
electron transport chain; the increase in free radicals causes
further damage to mtDNA, creating a vicious cycle. That the
association between the accumulation of mtDNA mutations and aging
is likely not an epiphenomenon is indicated by the striking
premature aging phenotype of transgenic mice with an increased
mtDNA mutation rate due to expression of a proof-reading-defective
mitochondrial DNA polymerase.
[0002] Loss of mitochondrial function, particularly complex 1
function, likely contributes to Parkinson's disease (PD) as well.
Complex I (NADH-ubiquinone oxidoreductase) activity is selectively
decreased 15-30% in the substantia nigra (SN) in sporadic PD.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin
that causes a parkinsonian syndrome in humans and mice: MPTP is
metabolized in the brain to MPP+, a complex I inhibitor that
accumulates in dopaminergic neurons. Chronic inhibition of complex
I with rotenone, throughout the brain, causes selective
degeneration of dopaminergic neurons in the SN. Rotenone-treated
rats develop all the pathological hallmarks of PD, including
distribution of pathology, nigrostriatal dopaminergic
neurodegeneration, formation of Lewy-Body-like cytoplasmic
inclusions, and oxidative damage. The hypokinesia in rats treated
with rotenone may also reflect, at least in part, a general health
problem rather than loss of nigrostriatal dopaminergic neurons.
[0003] A role for mitochondrial dysfunction in Friedreich's ataxia
(FRDA or FA) is also recognized. FRDA is an inherited disease that
causes progressive damage to the nervous system and muscle cells
resulting in symptoms ranging from uncoordination, gait
disturbance, and speech problems to heart disease and muscle
faiigueabilily. FRDA has a prevalence of approximately 1 in 40,000
in Caucasians. FRDA is characterized by progressive ataxia of all
four limbs, dysarthria, aneflexia, sensory loss, and exercise
intolerance. Skeletal deformities and cardiomyopathy are found in
most patients, impaired glucose tolerance and diabetes mellitus are
found in 30% of patients, and reduced visual acuity, including a
pigmentary retinopathy, and hearing loss are occasionally seen.
Symptoms usually begin between the ages of 5 and 15 but can, on
rare occasions, appear as early as 18 months or as late as 50 years
of age. The first symptom to appear is usually difficulty in
walking, or gait ataxia. The ataxia gradually worsens and slowly
spreads to the arms and then the trunk. Foot deformities such as
clubfoot, flexion (involuntary bending) of the toes, hammer toes,
or foot inversion (turning inward) may be early signs. Over time,
muscles begin to atrophy, especially in the feet, lower legs, and
hands, and deformities develop. Other symptoms include kiss of deep
tendon reflexes, especially in the knees and ankles. Generally,
within 10 to 20 years after the appearance of the first symptoms,
afflicted individuals are confined to a wheelchair, and in later
stages of the disease become completely incapacitated. Life
expectancy may be affected, and many people with FRDA die in
adulthood from the associated heart disease: myocardial failure is
the most common cause of premature death
(http://www.ninds.nih.gov/disorders/friedreichs_ataxia). There are
currently no approved treatments for FRDA.
[0004] Friedreich's ataxia is an autosomal recessive disease caused
by a triplet repeat expansion in the frataxin gene, which leads to
decreased frataxin protein levels. Frataxin is found primarily in
mitochondria where it chaperones iron for the formation of
iron-sulfur clusters and may also act to store and detoxify excess
iron. Iron-sulfur clusters are important prosthetic groups in the
mitochondrial electron transport chain and other enzymes, including
aconitase in the Krebs cycle. Decreased frataxin levels contribute
to mitochondrial dysfunction and mitochondrial iron accumulation,
which are believed to lead to increased production of toxic
oxidants, which can further impair mitochondrial and cellular
function. Mitochondrial dysfunction is believed to be responsible
for most, if not all, of the pathologies described above.
SUMMARY OF THE INVENTION
[0005] In one embodiment, a method is provided for increasing
cellular frataxin gene expression or the phenotype thereof in a
subject comprising administering to the subject an effective amount
of a compound of formula (I) or a pharmaceutical composition
thereof:
##STR00002## [0006] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0007] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0008] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0009] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0010] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0011] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0012] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0013] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy, in other embodiments, A is
a substituted aryl group or an optionally substituted furyl group.
In further embodiments, R.sup.3 is an optionally substituted alkyl
or aralkyl group.
[0014] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00003## [0015] wherein B is O, N or S; [0016] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0017] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0018] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0019] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0020] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0021] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0022] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0023] In certain embodiments. R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0024] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, B is O. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0025] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0026] In certain other embodiments, compound (I) has the structure
of formula (III)
##STR00004## [0027] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0028] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0029] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0030] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0031] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0032] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0033] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0034] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R is hydroxy. In other embodiments, R.sup.3
can be alkyl or aralkyl.
[0035] In certain embodiments. R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0036] Non-limiting examples of such compounds include
N-[(3-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide.
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0037] In a further embodiment, the subject is a Friedreich's
ataxia patient or is at risk for developing Friedreich's
ataxia.
[0038] In another embodiment, a method is provided for increasing
cellular frataxin activity or level, or the phenotype thereof, in a
subject comprising administering to the subject an effective amount
of a compound of formula (I), formula (II) or formula (III) as
mentioned above, and such compounds noted above by way of
non-limiting example. In certain embodiments, the subject is a
Friedreich's ataxia patient or is at risk for developing
Friedreich's ataxia.
[0039] In yet another embodiment, a method is provided for
decreasing mitochondrial iron accumulation or level in a subject or
altering iron metabolism or homeostasis therein comprising
administering to the subject an effective amount of a compound of
formula (I), formula (II), or formula (III) mentioned above, and
such compounds noted above by way of non-limiting example. In
certain embodiments, the subject is a Friedreich's ataxia patient
or is at risk for developing Friedreich's ataxia. In other
embodiments, the subject is a patient or individual with or at risk
of developing a neurodegenerative disease, neurodegeneration with
brain iron accumulation (NBIA), Parkinson's disease, Alzheimer's
disease, a mitochondrial encephalopathy, normal aging,
hemochromatosis, aceruloplasminemia, thalassemia, attention deficit
hyperactivity disorder (ADHD), Tourette's syndrome, diabetes, or
age-related macular degeneration. In another embodiment the subject
has an iron overload disease or a predisposition or risk of
developing an iron overload disease.
[0040] In yet another embodiment, a method is provided for
decreasing cellular iron import in a subject comprising
administering to a subject in need thereof an effective amount of a
compound of formula (I), formula (II) or formula (III) mentioned
above, and such compounds noted above by way of non-limiting
example. In certain embodiments, the subject is a Friedreich's
ataxia patient or is at risk for developing Friedreich's ataxia. In
other embodiments, the subject is a patient or individual with or
at risk of developing a neurodegenerative disease,
neurodegeneration with brain iron accumulation (NBIA), Friedreich's
ataxia, Parkinson's disease, Alzheimer's disease, a mitochondrial
encephalopathy, normal aging, hemochromatosis, aceruloplasminemia,
thalassemia, attention deficit hyperactivity disorder (ADHD),
Tourette's syndrome, diabetes, or age-related macular
degeneration.
[0041] In another embodiment, a method is provided for improving
mitochondrial or cellular respiratory activity or function in a
subject comprising administering to the subject an effective amount
of a compound of formula (I), formula (II) or formula (III)
mentioned above, and such compounds noted above by way of
non-limiting example. In certain embodiments, the subject is a
Friedreich's ataxia patient or is at risk for developing
Friedreich's ataxia. In other embodiments, the subject is a patient
or individual with or at risk of developing a neurodegenerative
disease, neurodegeneration with brain iron accumulation (NBIA),
Friedreich's ataxia, Parkinson's disease, Alzheimer's disease, a
mitochondrial encephalopathy, normal aging, hemochromatosis,
aceruloplasminemia, thalassemia, attention deficit hyperactivity
disorder (ADHD), Tourette's syndrome, diabetes, or age-related
macular degeneration.
[0042] In another embodiment, a method is provided for compensating
for frataxin deficiency or mutation in a cell, tissue or subject
comprising exposing to the cell or tissue or administering to the
subject an effective amount of a compound of formula (I), formula
(II) or formula (III) mentioned above, and such compounds noted
above by way of non-limiting example. In certain embodiments, the
subject is a Friedreich's ataxia patient or is at risk for
developing Friedreich's ataxia. In other embodiments, the subject
is a patient or individual with or at risk of developing a
neurodegenerative disease, neurodegeneration with brain iron
accumulation (NBIA), Friedreich's ataxia, Parkinson's disease,
Alzheimer's disease, a mitochondrial encephalopathy, normal aging,
hemochromatosis, aceruloplasminemia, thalassemia, attention deficit
hyperactivity disorder (ADHD), Tourette's syndrome, diabetes, or
age-related macular degeneration.
[0043] In another embodiment, a method is provided for decreasing
or reducing oxidative stress in the mitochondria, cells, tissues,
or any combination thereof in a subject comprising administering to
the subject an effective amount of a compound of formula (I),
formula (II) or formula (III) mentioned above, and such compounds
noted above by way of non-limiting example. In certain embodiments,
the subject is a Friedreich's ataxia patient or is at risk for
developing Friedreich's ataxia. In other embodiments, the subject
is a patient or individual with or at risk of developing a
neurodegenerative disease, neurodegeneration with brain iron
accumulation (NBIA), Friedreich's ataxia, Parkinson's disease,
Alzheimer's disease, a mitochondrial encephalopathy, normal aging,
hemochromatosis, aceruloplasminemia, thalassemia, attention deficit
hyperactivity disorder (ADHD), Tourette's syndrome, diabetes, or
age-related macular degeneration.
[0044] In another embodiment, a method is provided for treating a
subject suffering from Friedreich's ataxia or reducing the symptoms
thereof comprising administering to the subject an effective amount
of a compound of formula (I) or a pharmaceutical composition
thereof:
##STR00005## [0045] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0046] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0047] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0048] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0049] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0050] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0051] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0052] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments, A is
a substituted aryl group or an optionally substituted fury group.
In further embodiments, R.sup.3 is an optionally substituted alkyl
or aralkyl group.
[0053] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00006## [0054] wherein B is O, N or S; [0055] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0056] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0057] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0058] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0059] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0060] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0061] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0062] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0063] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, B is O. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0064] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0065] In certain other embodiments, compound (I) has the structure
of formula (III)
##STR00007## [0066] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0067] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0068] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0069] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0070] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0071] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0072] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0073] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0074] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0075] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0076] In a further embodiment, the foregoing subject can be at
risk for developing Friedreich's ataxia.
[0077] In another embodiment, a method is provided for treating a
subject having a disease or condition or at risk for developing a
disease or dysfunction characterized by mitochondrial dysfunction,
iron accumulation or increased cellular oxidative stress,
comprising administering to the subject an effective amount of a
compound of formula (I) or a pharmaceutical composition
thereof:
##STR00008## [0078] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0079] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0080] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0081] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0082] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0083] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0084] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0085] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments, A is
a substituted aryl group or an optionally substituted furyl group.
In further embodiments, R.sup.3 is an optionally substituted alkyl
or aralkyl group.
[0086] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00009## [0087] wherein B is O, N or S; [0088] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0089] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0090] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0091] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0092] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0093] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0094] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0095] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R is hydroxy. In other embodiments, R.sup.3
can be alkyl or aralkyl.
[0096] In certain embodiments. R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, B is O. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0097] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0098] In certain other embodiments, compound (I) has the structure
of formula (III)
##STR00010## [0099] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0100] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0101] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0102] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0103] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0104] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0105] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0106] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0107] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0108] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0109] In other embodiments, methods are provided for treating a
subject having or at risk for developing a neurodegenerative
disease, neurodegeneration with brain iron accumulation (NBIA),
Friedreich's ataxia, Parkinson's disease, Alzheimer's disease, a
mitochondrial encephalopathy, normal aging, hemochromatosis,
aceruloplasminemia, thalassemia, attention deficit hyperactivity
disorder (ADHD), Tourette's syndrome, diabetes, or age-related
macular degeneration, comprising administering to the subject an
effective amount of a compound of formula (I) or a pharmaceutical
composition thereof:
##STR00011## [0110] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0111] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0112] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0113] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0114] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0115] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0116] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0117] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments, A is
a substituted aryl group or an optionally substituted furyl group.
In further embodiments, R.sup.3 is an optionally substituted alkyl
or aralkyl group.
[0118] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00012## [0119] wherein B is O, N or S; [0120] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0121] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0122] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0123] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0124] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0125] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0126] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0127] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R is hydroxy. In other embodiments, R.sup.3
can be alkyl or aralkyl.
[0128] In certain embodiments. R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, B is O. In further embodiments,
R.sup.J is an optionally substituted alkyl or aralkyl group.
[0129] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0130] In certain other embodiments, compound (I) has the structure
of formula (III)
##STR00013## [0131] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0132] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0133] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0134] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0135] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0136] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0137] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0138] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0139] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0140] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0141] In another embodiment, a method is provided for identifying
a step in mitochondrial function or cellular respiration upstream
from or regulated by frataxin activity or the phenotype thereof,
and for identifying candidate activity modulators of such step. In
one embodiment, the method comprises determining the effect on
mitochondrial function or cellular respiration of at least one
candidate modulator in cells that are frataxin deficient,
frataxin-mutated, or in frataxin knockout cells, in the presence
and absence of a compound of formula (I), (II) or (III) described
herein above
[0142] In a further embodiment, the effect of the at least one
candidate modulator on mitochondrial function, iron homeostasis,
resistance to oxidants and/or added iron, or cellular respiration
in the presence and absence of the compound of formula (I), (II) or
(III) is correlated with the relationship of the step to that of
frataxin activity, its role in regulation thereof, and
identification of a modulator thereof. In a further embodiment, the
at least one candidate modulator of the step is a compound that
modulates activity of the step, or a mutation that modulates the
step, or the combination thereof. In another embodiment, the
mutation inhibits the step and the compound is a candidate
activator of or phenotypic substitute for the step. In another
embodiment, the frataxin deficient, frataxin-mutated, or frataxin
knockout cells are yeast cells or mammalian cells, and in further
embodiments, the yeast cells have at least one gene encoding a
protein catalyzing or regulating the step knocked out or regulated
by an inducible promoter; or the yeast cells also have the frataxin
gene knocked out or regulated by an inducible promoter. In another
embodiment, the compound has formula (II) or formula (III) as
described hereinabove, or any embodiment thereof.
[0143] In another embodiment, a method is provided for identifying
cells, tissues, or cells or tissues from a subject that may have a
defect in mitochondrial function, cellular respiration upstream
from or regulated by frataxin activity or the phenotype thereof,
comprising determining the effect on mitochondrial function or
cellular respiration in said cells or tissues by a compound of
formula (I), (II) or (III) as described hereinabove.
[0144] In another embodiment, compounds and pharmaceutical
compositions of such compounds useful for the purposes herein are
provided having the structure of formula (I):
##STR00014## [0145] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0146] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0147] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0148] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0149] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0150] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0151] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0152] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments, A is
a substituted aryl group or an optionally substituted furyl group.
In further embodiments, R.sup.5 is an optionally substituted alkyl
or aralkyl group.
[0153] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00015## [0154] wherein B is O, N or S; [0155] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0156] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0157] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0158] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0159] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0160] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0161] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0162] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0163] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, B is O. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0164] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0165] In certain other embodiments, compound (I) has the structure
of formula (III)
##STR00016## [0166] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0167] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0168] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0169] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0170] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0171] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0172] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0173] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments,
R.sup.3 can be alkyl or aralkyl.
[0174] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments. R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups. In further embodiments,
R.sup.3 is an optionally substituted alkyl or aralkyl group.
[0175] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
Definitions
[0176] It is understood that the compounds, as described herein,
may be substituted with any number of substituents or functional
moieties. In general, the term "substituted" whether preceded by
the term "optionally" or not, and substituents contained in
formulas of this invention, refer to the replacement of hydrogen
radicals in a given structure with the radical of a specified
substituent. When more than one position in any given structure may
be substituted with more than one substituent selected from a
specified group, the substituent may be either the same or
different at every position. As used herein, the term "substituted"
is contemplated to include all permissible substituents of organic
compounds. In a broad aspect the permissible substituents include
acyclic and cyclic, branched and unbanked, carbocyclic and
heterocyclic, aromatic and non-aromatic, carbon and heteroatom
substituents of organic compounds. For purposes of this invention,
heteroatoms such as nitrogen may have hydrogen substituents and/or
any permissible substituents of organic compounds described herein
which satisfy the valencies of the heteroatoms. Furthermore, this
invention is not intended to be limited in any manner by the
permissible substituents of organic compounds. Combinations of
substituents and variables envisioned by this invention are
preferably those that result in the formation of stable compounds
useful in the treatment and prevention, for example of disorders,
as described generally above. Examples of substituents include, but
are not limited to aliphatic; heteroaliphatic; alicyclic;
heterocyclic; aromatic, heteroaromatic; aryl; heteroaryl;
alkylaryl; aralkyl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy;
heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; or -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --C(.dbd.O)--, --S(.dbd.O)--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)--, --OC(.dbd.O)O--, --OC(.dbd.O)NR.sup.G2--,
--NR.sup.G2C(.dbd.O)O--, --NR.sup.G2C(.dbd.O)NR.sup.G2--,
--C(.dbd.S)--, --C(.dbd.S)S--, --SC(.dbd.S)--, --SC(.dbd.S)S--,
--C(.dbd.NR.sup.G2)--, --C(.dbd.NR.sup.G2)O--,
--C(.dbd.NR.sup.G2)NR.sup.G3--, --OC(.dbd.NR.sup.G2)--,
--NR.sup.G2C(.dbd.NR.sup.G3)--, --NR.sup.G2SO.sub.2--,
--NR.sup.G2SO.sub.2NR.sup.G3--, or --SO.sub.2NR.sup.G2--, wherein
each occurrence of R.sup.G1, R.sup.G2 and R.sup.G3 independently
includes, but is not limited to, hydrogen, halogen, or an
optionally substituted aliphatic, heteroaliphatic, alicyclic,
heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl,
alkylaryl, or alkylheteroaryl moiety.
[0177] The term "stable", as used herein, preferably refers to
compounds which possess stability sufficient to allow manufacture
and which maintain the integrity of the compound for a sufficient
period of time to be detected and preferably for a sufficient
period of lime to be useful for the purposes detailed herein.
[0178] The term "aliphatic", as used herein, includes both
saturated and unsaturated, straight chain (i.e., unbranched) or
branched aliphatic hydrocarbons as defined by IUPAC, which are
optionally substituted with one or more functional groups. As
defined herein, "aliphatic" is intended to include optionally
substituted alkyl, alkenyl and alkynyl moieties. Thus, as used
herein, the term "alkyl" includes straight and branched alkyl
groups. An analogous convention applies to other generic terms such
as "alkenyl", "alkynyl" and the like. Furthermore, as used herein,
the terms "alkyl", "alkenyl", "alkynyl" and the like encompass both
substituted and unsubstituted groups. In certain embodiments, as
used herein, "lower alkyl" is used to indicate those alkyl groups
(substituted, unsubstituted, branched or unbranched) having about
1-6 carbon atoms. In some instances aliphatic can include alicyclic
or cycloalkyl, including unsaturations therein.
[0179] In certain embodiments, the alkyl, alkenyl and alkynyl
groups employed in the invention contain 1-20; 2-20; 3-20; 4-20;
5-20; 6-20; 7-20 or 8-20 aliphatic carbon atoms. In certain other
embodiments, the alkyl, alkenyl, and alkynyl groups employed in the
invention contain 1-10; 2-10; 3-10; 4-10; 5-10; 6-10; 7-10 or 8-10
aliphatic carbon atoms. In yet other embodiments, the alkyl,
alkenyl, and alkynyl groups employed in the invention contain 1-8;
2-8; 3-8; 4-8; 5-8; 6-20 or 7-8 aliphatic carbon atoms. In still
other embodiments, the alkyl, alkenyl, and alkynyl groups employed
in the invention contain 1-6; 2-6; 3-6; 4-6 or 5-6 aliphatic carbon
atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl
groups employed in the invention contain 1-4; 2-4 or 3-4 carbon
atoms. Illustrative aliphatic groups thus include, but are not
limited to, for example, methyl, ethyl, n-propyl, isopropyl, allyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, sec-pentyl,
isopentyl, tert-pentyl, n-hexyl, sec-hexyl, moieties and the like,
which again, may bear one or more substituents. Alkenyl groups
include, but are not limited to, for example, ethenyl, propenyl,
butenyl, 1-methyl-2-buten-1-yl, and the like. Representative
alkynyl groups include, but are not limited to, ethynyl, 2-propynyl
(propargyl), 1-propynyl and the like.
[0180] The term "alicyclic", as used herein, refers to compounds
that combine the properties of aliphatic and cyclic compounds and
include but are not limited to cyclic, or polycyclic aliphatic
hydrocarbons and bridged cycloalkyl compounds, which are optionally
substituted with one or more functional groups. As will be
appreciated by one of ordinary skill in the art, "alicyclic" is
intended herein to include, but is not limited to, cycloalkyl,
cycloalkenyl, and cycloalkynyl moieties, which are optionally
substituted with one or more functional groups. Illustrative
alicyclic groups thus include, but are not limited to, for example,
cyclopropyl, --CH.sub.2-cyclopropyl, cyclobutyl,
--CH.sub.2-cyclobutyl, cyclopentyl, --CH.sub.2-cyclopentyl-n,
cyclohexyl, --CH.sub.2-cyclohexyl, cyclohexenylethyl,
cyclohexanylethyl, norborbyl moieties and the like, which again,
may bear one or more substituents.
[0181] The term "cycloalkyl", as used herein, refers to cyclic
alkyl groups, specifically to groups having three to seven,
preferably three to ten carbon atoms. Suitable cycloalkyls include,
but are not limited to cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl and the like, which, as in the case of
aliphatic, heteroaliphatic or heterocyclic moieties, may optionally
be substituted. An analogous convention applies to other generic
terms such as "cycloalkenyl", "cycloalkynyl" and the like.
[0182] The term "heteroaliphatic", as used herein, refers to
aliphatic moieties in which one or more carbon atoms in the main
chain have been replaced with a heteroatom. Thus, a heteroaliphatic
group refers to an aliphatic chain which contains one or more
oxygen, sulfur, nitrogen, phosphorus or silicon atoms in place of
carbon atoms in the aliphatic main chain. Heteroaliphatic moieties
may be branched or linear unbranched. In certain embodiments,
heteroaliphatic moieties are substituted by independent replacement
of one or more of the hydrogen atoms thereon with one or more
moieties including, but not limited to aliphatic; heteroaliphatic;
alicyclic; heterocyclic; aromatic, heteroaromatic; aryl;
heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; or -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --C(.dbd.O)--, --S(.dbd.O)--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)--, --OC(.dbd.O)O--, --OC(.dbd.O)NR.sup.G2--,
--NR.sup.G2C(.dbd.O)O--, --NR.sup.G2C(.dbd.O)NR.sup.G2--,
--C(.dbd.S)--, --C(.dbd.S)S--, --SC(.dbd.S)--, --SC(.dbd.S)S--,
--C(.dbd.NR.sup.G2)--, --C(.dbd.NR.sup.G2)O--,
--C(.dbd.NR.sup.G2)NR.sup.G3--, --OC(.dbd.NR.sup.G2)--,
--NR.sup.G2C(.dbd.NR.sup.G3)--, --NR.sup.G2SO.sub.2--,
--NR.sup.G2SO.sub.2NR.sup.G3--, or --SO.sub.2NR.sup.G2--, wherein
each occurrence of R.sup.G1, R.sup.G2 and R.sup.G3 independently
includes, but is not limited to, hydrogen, halogen, or an
optionally substituted aliphatic, heteroaliphatic, alicyclic,
heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl,
alkylaryl, or alkylheteroaryl moiety.
[0183] The term "heteroalicyclic", "heterocycloalkyl" or
"heterocyclic", as used herein, refers to compounds which combine
the properties of heteroaliphatic and cyclic compounds and include
but are not limited to saturated and unsaturated mono- or
polycyclic ring systems having 5-16 atoms wherein at least one ring
atom is a heteroatom selected from O, S and N (wherein the nitrogen
and sulfur heteroatoms may be optionally be oxidized), wherein the
ring systems are optionally substituted with one or more functional
groups, as defined herein. In certain embodiments, the term
"heterocyclic" refers to a non-aromatic 5-, 6- or 7-membered ring
or a polycyclic group, including, but not limited to a bi- or
tri-cyclic group comprising fused six-membered rings having between
one and three heteroatoms independently selected from oxygen,
sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 2
double bonds and each 6-membered ring has 0 to 2 double bonds, (ii)
the nitrogen and sulfur heteroatoms may optionally be oxidized,
(iii) the nitrogen heteroatom may optionally be quaternized, and
(iv) any of the above heterocyclic rings may be fused to an aryl or
heteroaryl ring. Representative heterocycles include, but are not
limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl imidazolinyl,
imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl,
isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and
tetrahydrofuryl. In certain embodiments, a "substituted
heterocycloalkyl or heterocycle" group is utilized and as used
herein, refers to a heterocycloalkyl or heterocycle group, as
defined above, substituted by the independent replacement of one or
more hydrogen atoms thereon with aliphatic; heteroaliphatic;
alicyclic; heterocyclic; aromatic, heteroaromatic; aryl;
heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; or -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --C(.dbd.O)--, --S(.dbd.O)--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)--, --OC(.dbd.O)O--, --OC(.dbd.O)NR.sup.G2--,
--NR.sup.G2C(.dbd.O)O--, --NR.sup.G2C(.dbd.O)NR.sup.G2--,
--C(.dbd.S)--, --C(.dbd.S)S--, --SC(.dbd.S)--, --SC(.dbd.S)S--,
--C(.dbd.NR.sup.G2)--, --C(.dbd.NR.sup.G2)O--,
--C(.dbd.NR.sup.G2)NR.sup.G3--, --OC(.dbd.NR.sup.G2)--,
--NR.sup.G2C(.dbd.NR.sup.G3)--, --NR.sup.G2SO.sub.2--,
--NR.sup.G2SO.sub.2NR.sup.G3--, or --SO.sub.2NR.sup.G2--, wherein
each occurrence of R.sup.G1, R.sup.G2 and R.sup.G3 independently
includes, but is not limited to, hydrogen, halogen, or an
optionally substituted aliphatic, heteroaliphatic, alicyclic,
heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl,
alkylaryl, or alkylheteroaryl moiety.
[0184] Additionally, it will be appreciated that any of the
alicyclic or heterocyclic moieties described above and herein may
comprise an aryl or heteroaryl moiety fused thereto.
[0185] In general, the term "aromatic moiety", as used herein,
refers to a stable mono- or polycyclic, unsaturated moiety having
preferably 3-14 carbon atoms, each of which may be substituted or
unsubstituted. In certain embodiments, the term "aromatic moiety"
refers to a planar ring having p-orbitals perpendicular to the
plane of the ring at each ring atom and satisfying the Huckel rule
where the number of pi electrons in the ring is (4n+2) wherein n is
an integer. A mono- or polycyclic, unsaturated moiety that does not
satisfy one or all of these criteria for aromaticity is defined
herein as "non-aromatic", and is encompassed by the term
"alicyclic". Examples of aromatic moieties include, but are not
limited to, phenyl, indanyl, indenyl, naphthyl, phenanthryl and
anthracyl.
[0186] In general, the term "heteroaromatic moiety", as used
herein, refers to stable substituted or unsubstituted unsaturated
mono-heterocyclic or polyheterocyclic moieties having preferably
3-14 carbon atoms, comprising at least one ring having p-orbitals
perpendicular to the plane of the ring at each ring atom, and
satisfying the Huckel rule where the number of pi electrons in the
ring is (4n+2) wherein n is an integer. Examples of heteroaromatic
moieties include, but are not limited to, pyridyl, quinolinyl,
dihydroquinolinyl, isoquinolinyl, quinazolinyl, dihydroquinazolyl,
and tetrahydroquinazolyl.
[0187] It will also be appreciated that aromatic and heteroaromatic
moieties, as defined herein, may be attached via an aliphatic
(e.g., alkyl) or heteroaliphatic (e.g., heteroalkyl) moiety and
thus also include moieties such as -(aliphatic)aromatic,
-(heteroaliphatic)aromatic, -(aliphatic)heteroaromatic,
-(heteroaliphatic)heteroaromatic, -(alkyl)aromatic,
-(heteroalkyl)aromatic, -(alkyl)heteroaromatic, and
-(heteroalkyl)heteroaromatic moieties. Thus, as used herein, the
phrases "aromatic or heteroaromatic moieties" and "aromatic,
heteroaromatic, -(alkyl)aromatic, -(heteroalkyl)aromatic,
-(heteroalkyl)heteroaromatic, and -(heteroalkyl)heteroaromatic" are
interchangeable. In some instances corresponding moieties may be
referred to synonymously as aralkyl, heteroaralkyl and the like.
Substituents include, but are not limited to, any of the previously
mentioned substituents, i.e., the substituents recited for
aliphatic moieties, or for other moieties as disclosed herein,
resulting in the formation of a stable compound.
[0188] "Aralkyl," also called "arylalkyl," refers to an aryl group
terminating with an aliphatic group, such as a benzyl, phenylethyl,
phenylpropyl, or phenylbutyl group, etc. The aryl moiety may be
substituted as generally described herein, as may be the aliphatic
moiety. The aliphatic moiety may be as defined above, such as an
alkyl, alkenyl or alkynyl group.
[0189] In general, the term "aryl" refers to aromatic moieties, as
described above, excluding those attached via an aliphatic (e.g.,
alkyl) or heteroaliphatic (e.g., heteroalkyl) moiety. In certain
embodiments of the present invention, "aryl" refers to a mono- or
bicyclic carbocyclic ring system having one or two rings satisfying
the Huckel rule for aromaticity, including, but not limited to,
phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the
like.
[0190] Similarly, the term "heteroaryl" refers to heteroaromatic
moieties, as described above, excluding those attached via an
aliphatic (e.g., alkyl) or heteroaliphatic (e.g., heteroalkyl)
moiety. In certain embodiments of the present invention, the term
"heteroaryl", as used herein, refers to a cyclic unsaturated
radical having from about five to about ten ring atoms of which one
ring atom is selected from S, O and N; zero, one or two ring atoms
are additional heteroatoms independently selected from S, O and N;
and the remaining ring atoms are carbon, the radical being joined
to the rest of the molecule via any of the ring atoms, such as, for
example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl,
imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl,
oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and
the like.
[0191] As defined herein, "aryl" and "heteroaryl" groups (including
bicyclic aryl groups) can be unsubstituted or substituted, wherein
substitution includes replacement of one or more of the hydrogen
atoms thereon independently with any of the previously mentioned
substituents. i.e., the substituents recited for aliphatic
moieties, or for other moieties as disclosed herein, resulting in
the formation of a stable compound. For example, aryl and
heteroaryl groups (including bicyclic aryl groups) can be
unsubstituted or substituted, wherein substitution includes
replacement of one or more of the hydrogen atoms thereon
independently with any one or more of the following moieties
including, but not limited to: aliphatic; heteroaliphatic;
alicyclic; heterocyclic; aromatic, heteroaromatic; aryl;
heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; or -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --C(.dbd.O)--, --S(.dbd.O)--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)--, --OC(.dbd.O)O--, --OC(.dbd.O)NR.sup.G2--,
--NR.sup.G2C(.dbd.O)O--, --NR.sup.G2C(.dbd.O)NR.sup.G2--,
--C(.dbd.S)--, --C(.dbd.S)S--, --SC(.dbd.S)--, --SC(.dbd.S)S--,
--C(.dbd.NR.sup.G2)--, --C(.dbd.NR.sup.G2)O--,
--C(.dbd.NR.sup.G2)NR.sup.G3--, --OC(.dbd.NR.sup.G2)--,
--NR.sup.G2C(.dbd.NR.sup.G3)--, --NR.sup.G2SO.sub.2--,
--NR.sup.G2SO.sub.2NR.sup.G3--, or --SO.sub.2NR.sup.G2--, wherein
each occurrence of R.sup.G1, R.sup.G2 and R.sup.G3 independently
includes, but is not limited to, hydrogen, halogen, or an
optionally substituted aliphatic, heteroaliphatic, alicyclic,
heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl,
alkylaryl, or alkylheteroaryl moiety. Additionally, it will be
appreciated, that any two adjacent groups taken together may
represent a 4, 5, 6, or 7-membered substituted or unsubstituted
alicyclic or heterocyclic moiety.
[0192] The term "alkoxy" or "alkyloxy", as used herein refers to a
saturated (i.e., O-alkyl) or unsaturated (i.e., O-alkenyl and
O-alkynyl) group attached to the parent molecular moiety through an
oxygen atom. In certain embodiments, the alkyl group contains 1-20;
2-20; 3-20; 4-20; 3-20; 6-20; 7-20 or 8-20 aliphatic carbon atoms.
In certain other embodiments, the alkyl group contains 1-10; 2-10;
3-10; 4-10; 5-10; 6-10; 7-10 or 8-10 aliphatic carbon atoms. In yet
other embodiments, the alkyl, alkenyl, and alkynyl groups employed
in the invention contain 1-8; 2-8; 3-8; 4-8; 5-8; 6-20 or 7-8
aliphatic carbon atoms. In still other embodiments, the alkyl group
contains 1-6; 2-6; 3-6; 4-6 or 5-6 aliphatic carbon atoms. In yet
other embodiments, the alkyl group contains 1-4; 2-4 or 3-4
aliphatic carbon atoms. Examples of alkoxy, include but are not
limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy,
r-butoxy, sec-butoxy, tert-butoxy, neopentoxy, n-hexoxy and the
like.
[0193] The term "thioalkyl" as used herein refers to a saturated
(i.e., S-alkyl) or unsaturated (i.e., S-alkenyl and S-alkynyl)
group attached to the parent molecular moiety through a sulfur
atom. In certain embodiments, the alkyl group contains 1-20
aliphatic carbon atoms. In certain other embodiments, the alkyl
group contains 1-10 aliphatic carbon atoms. In yet other
embodiments, the alkyl, alkenyl, and alkynyl groups employed in the
invention contain 1-8 aliphatic carbon atoms. In still other
embodiments, the alkyl group contains 1-6 aliphatic carbon atoms.
In yet other embodiments, the alkyl group contains 1-4 aliphatic
carbon atoms. Examples of thioalkyl include, but are not limited
to, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio,
and the like.
[0194] The term "alkylamino" refers to a group having the structure
--NHR' wherein R' is aliphatic or alicyclic, as defined herein. The
term "aminoalkyl" refers to a group having the structure
NH.sub.2R'--, wherein R' is aliphatic or alicyclic, as defined
herein. In certain embodiments, the aliphatic or alicyclic group
contains 1-20 aliphatic carbon atoms. In certain other embodiments,
the aliphatic or alicyclic group contains 1-10 aliphatic carbon
atoms. In still other embodiments, the aliphatic or alicyclic group
contains 1-6 aliphatic carbon atoms. In yet other embodiments, the
aliphatic or alicyclic group contains 1-4 aliphatic carbon atoms.
In yet other embodiments, R' is an alkyl, alkenyl, or alkynyl group
containing 1-8 aliphatic carbon atoms. Examples of alkylamino
include, but are not limited to, methylamino, ethylamino,
iso-propylamino and the like.
[0195] Some examples of substituents of the above-described
aliphatic (and other) moieties of compounds of the invention
include, but are not limited to aliphatic; alicyclic;
heteroaliphatic; heterocyclic; aromatic; heteroaromatic; aryl;
heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl;
heteroalkylheteroaryl; alkoxy; aryloxy; heteroalkoxy;
heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(.dbd.O)R.sub.x;
--CO.sub.2(R.sub.x); --C(.dbd.O)N(R.sub.x).sub.2;
--OC(.dbd.O)R.sub.x; --OCO.sub.2R.sub.x;
--OC(.dbd.O)N(R.sub.x).sub.2; --N(R.sub.x).sub.2; --OR.sub.x;
--SR.sub.x; --S(O)R.sub.x; --S(O).sub.2R.sub.x;
--NR.sub.x(CO)R.sub.x; --N(R.sub.x)CO.sub.2R.sub.x;
--N(R.sub.x)S(O).sub.2R.sub.x;
--N(R.sub.x)C(.dbd.O)N(R.sub.x).sub.2;
--S(O).sub.2N(R.sub.x).sub.2; wherein each occurrence of R.sub.x
independently includes, but is not limited to, aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl,
alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic,
heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl
substituents described above and herein may be substituted or
unsubstituted, branched or unbranched, saturated or unsaturated,
and wherein any of the aryl or heteroaryl substituents described
above and herein may be substituted or unsubstituted.
[0196] The terms "halo" and "halogen" as used herein refer to an
atom selected from fluorine, chlorine, bromine and iodine.
[0197] The term "haloalkyl" denotes an alkyl group, as defined
above, having one, two, or three halogen atoms attached thereto and
is exemplified by such groups as chloromethyl, bromoethyl,
trifluoromethyl, and the like.
[0198] The term "amino", as used herein, refers to a primary
(--NH.sub.2), secondary (--NHR.sub.x), tertiary (--NR.sub.xR.sub.y)
or quaternary (--N.sup.+R.sub.xR.sub.yR.sub.z) amine, where
R.sub.x, R.sub.y and R.sub.z are independently an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, as defined herein. Examples of amino groups
include, but are not limited to, methylamino, dimethyl amino,
ethylamino, diethylamino, diethylaminocarbonyl, methylethylamino,
iso-propylamino, piperidino, trimethylamino, and propylamino.
[0199] The term "acyl", as used herein, refers to a group having
the general formula --C(.dbd.O)R, where R is an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, as defined herein.
[0200] The term "C.sub.2-6alkenylene", as used herein, refers to a
substituted or unsubstituted, linear or branched unsaturated
divalent radical consisting solely of carbon and hydrogen atoms,
having from two to six carbon atoms, having a free valence "-" at
both ends of the radical, and wherein the unsaturation is present
only as double bonds and wherein a double bond can exist between
the first carbon of the chain and the rest of the molecule.
[0201] As used herein, the terms "aliphatic", "heteroaliphatic",
"alkyl", "alkenyl", "alkynyl", "heteroalkyl", "heteroalkenyl",
"heteroalkynyl", and the like encompass substituted and
unsubstituted, saturated and unsaturated, and linear and branched
groups. Similarly, the terms "alicyclic", "heterocyclic",
"heterocycloalkyl", "heterocycle" and the like encompass
substituted and unsubstituted, and saturated and unsaturated
groups. Additionally, the terms "cycloalkyl", "cycloalkenyl",
"cycloalkynyl", "heterocycloalkyl", "heterocycloalkenyl",
"heterocycloalkynyl", "aromatic", "heteroaromatic", "aryl",
"heteroaryl" and the like encompass both substituted and
unsubstituted groups.
[0202] The phrase "the phenotype thereof" refers to an effect that
is a partial, an equivalent, or in excess of the extent of the
effect of the preceding term or terms. For example, frataxin
depletion increases iron accumulation, increases oxidative stress
and causes mitochondrial dysfunction. Increasing cellular frataxin
gene expression results in the decrease in iron accumulation,
decrease in oxidative stress, or improving mitochondrial
dysfunction. In one embodiment, the phenotype of increasing
frataxin gene expression can produce a partial decrease in iron
accumulation, partial decrease in oxidative stress or partial
reduction of mitochondrial dysfunction. In another embodiment, the
phenotype of increasing frataxin gene expression can produce an
extent of decrease in iron accumulation, decrease in oxidative
stress or reduction of mitochondrial dysfunction equivalent to that
extent achieved by increasing frataxin gene expression. In another
embodiment, the phenotype of increasing frataxin gene expression
can produce an extent of decrease in iron accumulation, decrease in
oxidative stress or reduction of mitochondrial dysfunction that
exceeds that extent achieved by increasing frataxin gene
expression.
[0203] The term "compensating" or "compensate" in reference to
frataxin deficiency or mutation refers to the property of
increasing, improving, or restoring cellular biochemistry or
metabolism that is impaired by a frataxin deficiency or mutation,
or the phenotype thereof, wherein the compensating does not
necessarily involve, or altogether does not involve, a direct
effect on frataxin levels, expression or activity. In referring to
a compound embodied herein as compensating for frataxin deficiency
or mutation, the compound has the property in cells, tissues, or in
subjects, of increasing, improving, or restoring cellular
biochemistry or metabolism that is impaired by a frataxin
deficiency or mutation, wherein the compound does not necessarily
involve, or altogether dose not involve, a direct effect on
frataxin levels, expression or activity.
[0204] The phrase, "pharmaceutically acceptable derivative", as
used herein, denotes any pharmaceutically acceptable salt, ester,
or salt of such ester, of such compound, or any other adduct or
derivative which, upon administration to a patient, is capable of
providing (directly or indirectly) a compound as otherwise
described herein, or a metabolite or residue thereof.
Pharmaceutically acceptable derivatives thus include among others
prodrugs. A prodrug is a derivative of a compound, usually with
significantly reduced pharmacological activity, which contains an
additional moiety, which is susceptible to removal in vivo yielding
the parent molecule as the pharmacologically active species. An
example of a prodrug is an ester, which is cleaved in vivo to yield
a compound of interest Another example is an N-methyl derivative of
a compound, which is susceptible to oxidative metabolism resulting
in N-demethylation. Prodrugs of a variety of compounds, and
materials and methods for derivatizing the parent compounds to
create the prodrugs, are known and may be adapted to the present
invention.
[0205] The phrase, "active metabolite", refers to a biologically
active derivative of a compound that is formed when the compound is
metabolized. The term "metabolized," as used herein, refers to the
sum of the processes (including, but not limited to, hydrolysis
reactions and reactions catalyzed by enzymes, such as, oxidation
reactions) by which a particular substance is changed by an
organism. Thus, enzymes may produce specific structural alterations
to a compound. For example, cytochrome P450 catalyzes a variety of
oxidative and reductive reactions while uridine diphosphate
glucuronyl transferases catalyze the transfer of an activated
glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols,
carboxylic acids, amines and free sulfhydryl groups. Further
information on metabolism may be obtained from The Pharmacological
Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites
of the compounds disclosed herein can be identified either by
administration of compounds to a host and analysis of tissue
samples from the host, or by incubation of compounds with hepatic
cells in vitro and analysis of the resulting compounds. Both
methods are well known in the art. In some embodiments, a compound
is metabolized to pharmacologically active metabolites.
[0206] The term "isomers" refers to stereoisomers and/or
diastereomers of the compounds, as some of the foregoing compounds
can comprise one or more asymmetric centers, and thus can exist in
various such isomeric forms. Thus, inventive compounds and
pharmaceutical compositions thereof may be in the form of an
individual enantiomer, diastereomer or geometric isomer, or may be
in the form of a mixture of stereoisomers. In certain embodiments,
the compounds of the invention are enantiopure compounds. In
certain other embodiments, mixtures of stereoisomers or
diastereomers are provided. In other embodiments a compound is
racemic.
[0207] The term "geometrical isomers" refers to cis-trans
isomerism, syn-anti or E/Z isomerism based on the
Cahn-Ingold-Rrelog system. See March's Advanced Organic Chemistry:
Reactions, Mechanisms and Structures, Sixth Edition,
Wiley-Interscience, pages 182-195 (2007). The term "geometrical
isomers" as used herein, refers to compounds having double bond
with an E or Z configuration or cis-trans isomers of monocyclic or
fused ring systems.
[0208] Furthermore, certain compounds, as described herein may have
one or more double bonds that can exist as either the Z or E
isomer, unless otherwise indicated. The invention additionally
encompasses the compounds as individual isomers substantially free
of other isomers and alternatively, as mixtures of various isomers,
e.g., racemic mixtures of stereoisomers. In addition to the
above-mentioned compounds per se, this invention also encompasses
pharmaceutically acceptable derivatives of these compounds and
compositions comprising one or more compounds of the invention and
one or more pharmaceutically acceptable excipients or
additives.
[0209] The term "metal chelate" refers to a compound of the
invention that has bound one or more metal ions, such as but not
limited to iron or manganese, in any one or more of their ionic
forms.
DETAILED DESCRIPTION OF THE INVENTION
[0210] Friedreich's ataxia (FRDA) is an autosomal recessive
neurodegenerative disorder caused by mutations in the FXN gene,
which encodes the protein frataxin, and for which there are no
currently accepted treatments. It is the most common hereditary
ataxia and causes progressive damage to the nervous system,
particularly sensory neurons, resulting in symptoms ranging from
ataxia, muscle fatigability, and speech problems to hypertrophic
cardiomyopathy. Frataxin localizes to the mitochondrial matrix,
where it chaperones iron for the assembly of iron-sulfur clusters
that are then employed by a variety of respiratory and other
enzymes. Mitochondrial dysfunction is therefore the primary
underlying cause of the signs and symptoms of FRDA.
[0211] Beyond FRDA, mitochondrial dysfunction is a key contributor
to a number of other diseases and conditions for which effect
treatments remain elusive. Mitochondrial dysfunction elevates
levels of toxic, reactive oxygen species that damage DNA and other
cellular components. Abnormal iron homeostasis and mitochondrial
iron accumulation contributes to mitochondrial dysfunction.
Conditions and diseases including various neurodegenerative
diseases, as well as normal aging, complications of diabetes, and
age-related macular degeneration are but a few examples of such
diseases related to mitochondrial dysfunction or mitochondrial iron
accumulation. Others include neurodegeneration with brain iron
accumulation (NBIA), Parkinson's disease, Alzheimer's disease, a
mitochondrial encephalopathy, hemochromatosis, aceruloplasminemia,
thalassemia, attention deficit hyperactivity disorder (ADHD), and
Tourette's syndrome. Within neurodegenerative diseases, Parkinson's
disease. Alzheimer's disease, and mitochondrial encephalopathies
are believed to have a pathophysiological cause or at least a
component due to mitochondrial dysfunction. Compounds that improve
or restore defects in mitochondrial metabolism, whether or not in
the mitochondrial electron transport chain, are highly sought for
potential therapeutic applications or as means to help identify
targets in mitochondrial biochemistry to facilitate identifying
other therapeutic interventions. Thus, in one embodiment, compounds
described herein have been identified that improve mitochondrial
function. In another embodiment the compounds described herein
decrease iron accumulation, or improve or restore iron homeostasis.
In another embodiment the compounds described herein decrease
oxidative stress.
[0212] As will be seen in the examples below, a facile means for
screening and identifying compounds that restore the defect in
mitochondrial metabolism present in, for example, FRDA or other
defects, employs a yeast model system that recognizes that the
yeast protein Yfh1p is a close structural and functional homolog of
frataxin. This facilitates use of this yeast model system as a
screening tool for compounds that substitute or circumvent this
defect. Virtually every finding regarding the role of Yfh1p in
yeast has been confirmed for frataxin in human cells. In yeast,
mitochondrial function can be assayed by quantifying growth in
media containing a non-fermentable carbon source, such as glycerol.
A colorimetric assay using a tetrazolium dye such as WST-1, which
is reduced by cellular dehydrogenases, can then be used to
quantitatively monitor the metabolic activity of cells.
[0213] Frataxin can substitute for the yeast frataxin homologue,
Yfh1p, indicating that the two proteins are orthologues, and
virtually every finding regarding the role of Yfh1p in yeast has
been confirmed for frataxin in human cells. Yfh1p and frataxin
localize to the mitochondrial matrix. Yeast lacking Yfh1p exhibit
decreased activities of mitochondrial iron-sulfur-cluster enzymes,
impaired mitochondrial respiration, mitochondrial iron
accumulation, and sensitivity to oxidative stress. The myocardium
of patients with FRDA exhibits decreased activities of
mitochondrial iron-sulfur-cluster enzymes--including respiratory
complexes I, II, and III--as well as impaired mitochondrial
bioenergetics. Cultured fibroblasts from patients with FRDA
accumulate mitochondrial iron and are sensitive to oxidative
stress.
[0214] The best-characterized function of Yfh1p and frataxin is in
iron-sulfur-cluster assembly. Iron-sulfur clusters are prosthetic
groups important for the function of many mitochondrial
proteins--including aconitase and mitochondrial respiratory
complexes I, II, and III--as well as for the function of a number
of cytosolic proteins. Studies in yeast demonstrate that Yfh1p is
important for the initial assembly of iron-sulfur clusters on the
scaffold protein Isu1p. Regulated Yfh1p depletion decreases
iron-sulfur-cluster assembly for mitochondrial and cytosolic
iron-sulfur-cluster proteins in vivo, as well as in vitro using
mitochondrial extracts. Using RNA electrophoretic mobility shift
assays (REMSAs), it was found that in primary FRDA fibroblasts, the
iron-sulfur-cluster form of the cytosolic protein IRP1 is decreased
and the mRNA-binding form is increased relative to normal control
fibroblasts. Hence, Yfh1p and frataxin likely play a central role
in iron-sulfur-cluster assembly for both mitochondrial and
cytosolic proteins.
[0215] The yeast model system used to identify compounds capable of
improving mitochondrial function is described in detail in the
examples below. As will be seen, active compounds produced
statistically significant improvements in growth (>2-fold in
shaking flasks by absorbance at 630 nm) and in ATP production
(>3-fold by the CellTiter-Glo assay), demonstrating that the
positive effects were not specific to tetrazolium dye reduction per
se.
[0216] A further screen can be carried out to test the effects of
overloading the murine myoblast cell line C2C12 with iron, using
ferric ammonium citrate (FAC); of inhibiting the rate-limiting step
of glutathione synthesis, using L-buthionine (S,R)-sulfoximine
(BSO); and of combining the two at sub-lethal concentrations for
each. Approximately 4000 cells per well are plated in standard
medium in 96-well plates and FAC is added 4 hours later. The cells
are incubated overnight (20 h) in standard tissue-culture
incubators, after which BSO is added. After another overnight
incubation (24 h) ATP content is determined using the CellTiter-Glo
assay.
[0217] Thus, through the aforementioned screening, compounds with
the following structural formula (I) are found to be active:
##STR00017## [0218] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0219] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0220] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0221] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0222] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0223] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0224] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0225] By way of non-limiting example, moiety A can be a
substituted or unsubstituted heteroaryl group such as a thienyl,
pyrrolyl or furyl group. In certain embodiments A is 2-thienyl. In
other embodiments, A is a substituted or unsubstituted aryl group.
In other embodiments A is phenyl. In other embodiments A is a
heterocyclic group. In other embodiments A is substituted with one
or more alkyl, alkoxy or halo groups, such as but not limited to
methyl, methoxy or chloro. In certain embodiments A is
4-methylphenyl, 2-methoxyphenyl, or 3,4-dimethoxyphenyl.
[0226] In other embodiments, R.sup.3 is aralkyl or alkyl.
Non-limiting examples of aralkyl include phenyl, benzyl,
phenylethyl, phenylpropyl, phenylbutyl and phenylpentyl. The
foregoing aralkyl groups may be substituted on the aryl moiety, or
on the alkyl moiety, or both. Non-limiting examples of alkyl
include methyl, ethyl, n-propyl, 2-propyl, n-butyl, t-butyl,
n-pentyl and n-hexyl.
[0227] Among the aforementioned compounds of formula (I), two
groups of compounds of special interest are identified: formula
(II) and formula (III).
[0228] In another embodiment, compounds useful for the purposes
described herein throughout have the structure of formula (II)
below:
##STR00018## [0229] wherein B is O, N or S; [0230] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0231] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0232] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0233] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0234] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0235] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4;
[0236] or an isomer, enantiomer, racemate, prodrug, active
metabolite, metal chelate, or a pharmaceutically-acceptable
derivative or salt form of any of the foregoing.
[0237] In certain embodiments, B is O. In other embodiments B is S.
In further embodiments, R.sup.1 can be hydroxy, nitro or halogen.
In other embodiments R.sup.2 can be hydroxy, nitro or cyano. In
other embodiments, R.sup.3 can be alkyl or aralkyl. In other
embodiments R.sup.5 is one or more alkyl, alkoxy or halo groups,
such as but not limited to methyl, methoxy or chloro. Non-limiting
examples of aralkyl include phenyl, benzyl and phenylethyl. The
foregoing aralkyl groups may be substituted on the aryl moiety, or
on the alkyl moiety, or both. Non-limiting examples of alkyl
include methyl, ethyl, n-propyl, 2-propyl, n-butyl, t-butyl,
n-pentyl and n-hexyl.
[0238] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0239] In certain other embodiments, compound (I) has the structure
of formula (III) below:
##STR00019## [0240] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0241] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0242] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0243] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0244] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0245] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0246] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0247] In certain embodiments, R.sup.1 can be hydroxy, nitro or
halogen. In certain embodiments R.sup.2 can be hydroxy, nitro or
cyano. In other embodiments. R.sup.5 can be one or more alkyl,
alkoxy, halo or dimethylamino groups. In other embodiments R.sup.3
is alkyl or aralkyl. Non-limiting examples of aralkyl include
phenyl, benzyl and phenylethyl. The foregoing aralkyl groups may be
substituted on the aryl moiety, or on the alkyl moiety, or both.
Non-limiting examples of alkyl include methyl, ethyl, n-propyl,
2-propyl, n-butyl, t-butyl, n-pentyl and n-hexyl.
[0248] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0249] In still yet a further embodiment, a method is provided for
identifying a step in mitochondrial function or cellular
respiration upstream from or regulated by frataxin activity or its
phenotypic equivalent, and for identifying candidate activity
modulators of such step. In this embodiment, compounds embodied
herein may be described or referred to as probes. In one
embodiment, the method comprises determining the effect on
mitochondrial function or cellular respiration of at least one
candidate modulator in cells that are frataxin deficient,
frataxin-mutated, or in frataxin knockout cells, in the presence
and absence of a compound of formula (I):
##STR00020## [0250] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0251] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0252] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0253] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0254] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0255] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0256] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0257] Non-limiting examples of various embodiments and compounds
in formulas (I), (II) and (III) are mentioned hereinabove.
[0258] In a further embodiment, the effect of the at least one
candidate modulator on mitochondrial function, iron homeostasis or
cellular respiration in the presence and absence of the compound of
formula (I) is correlated with the relationship of the step to that
of frataxin activity, its role in regulation thereof, and
identification of a modulator thereof. In a further embodiment, the
at least one candidate modulator of the step is a compound that
modulates activity of the step, or a mutation that modulates the
step, or the combination thereof. In another embodiment, the
mutation inhibits the step and the compound is a candidate
activator of or phenotypic substitute for the step. In another
embodiment, the frataxin deficient, frataxin-mutated, or frataxin
knockout cells are yeast cells or mammalian cells, and in further
embodiments, the yeast cells have at least one gene encoding a
protein catalyzing or regulating the step knocked out or regulated
by an inducible promoter; or the yeast cells also have the frataxin
gene knocked out or regulated by an inducible promoter. In another
embodiment, the compound has formula (II) or formula (III) as
described hereinabove, or any embodiment thereof.
[0259] In the foregoing method, at least one candidate modulator of
said step can a compound that modulates activity of said step, or a
mutation that modulates said step, or the combination thereof. In
another embodiment, the mutation inhibits said step and the
compound is a candidate activator of or phenotypic substitute for
said step. By way of non-limiting examples, the frataxin deficient,
frataxin-mutated, or frataxin knockout cells are yeast cells or
mammalian cells. In one embodiment, the yeast cells have at least
one gene encoding a protein catalyzing or regulating a step knocked
out or regulated by an inducible promoter. In another embodiment
the yeast cells also have the frataxin gene knocked out or
regulated by an inducible promoter. In another embodiment, the
cells are mammalian cells, and in a further embodiment have a
mutation in the frataxin gene or another defect in frataxin
expression. In another embodiment, the mammalian cells are from a
patient having FRDA.
[0260] The foregoing method is best illustrated by a non-limiting
example. As mentioned above, a screening assay using a yeast model
system allows for the rapid and facile identification of compounds
capable of restoring mitochondrial dysfunction in cells deficient
in frataxin, as well as identify compounds capable of improving
mitochondrial function in general. Such methods are amenable for
the identification and use of probes having the structure of
formula (I) that give insight into specific steps within
mitochondrial metabolism, such as but not limited to the
mitochondrial electron transport chain (ETC). With the
demonstration of an important role for mitochondrial dysfunction in
normal aging, and in the pathophysiology of Alzheimer's Disease,
Parkinson's Disease, age-related macular degeneration, and type II
diabetes, as well as of rare diseases such as FRDA and the
mitochondrial encephalomyopathies, the embodiment herein of probe
development facilitates identifying pathways and then compounds
that can address such important diseases and be useful
therapeutically or prophylactically.
[0261] In one embodiment, a probe identified as described herein
takes advantage of the fact that the yeast protein Yfh1p is a
functional homologue of the FRDA disease protein, and that
compounds of formula (I) herein overcomes the defect in Yfh1p
conditional knock-out cells or cells lacking Yfh1p. In another
embodiment, the functional homology of the two proteins allows drug
screening initially using a yeast model system for FRDA, and, of
particular relevance, libraries of yeast strains in which another
gene in the yeast genome has been independently knocked out. This
permits, in another embodiment, to determine target pathways and
proteins affected by compounds in the yeast screen that are also
active in human cells.
[0262] In the practice of this embodiment, the following steps are
carried out:
[0263] 1. Conduct the primary screen in the yeast model of FRDA, as
described above and in the Examples, using WST reduction, to
identify compounds that improve mitochondrial function.
[0264] 2. Carry out a secondary screen in mammalian cells treated
with ferric ammonium citrate (FAC) and L-buthionine
(S,R)-sulfoximine (BSO), using ATP measurements, to identify those
compounds identified in step (1) above that are active in human or
other mammalian cells.
[0265] 3. Evaluate active compounds from step (2) above in yeast
lacking functional mitochondrial complex V, using ATP measurements,
to identify compounds that act in the ETC. Compounds that depend on
complex V for at least 50% of their activity will be carried
through to step 4.
[0266] 4. Evaluate active compounds from step (3) above in yeast
lacking functional mitochondrial complexes I, II, III, and IV to
identify specific sites of action within the ETC. Determine that
activity is dependent on a specific ETC respiratory complex.
[0267] 5. Evaluate compounds from step (4) above in mammalian cells
treated with inhibitors of specific complexes of the ETC to confirm
sites of action of compounds studied in steps 3 and 4. Confirm
activity is dependent on a specific respiratory complex.
[0268] Moreover, additional screens can be performed on the
compounds: [0269] 1. Evaluate compounds in HepG2 cells to determine
if they can be rescued from lethal or sublethal concentrations of
ferric ammonium citrate (FAC) and/or L-buthionine (S,R)-sulfoximine
(BSO). [0270] 2. Evaluate compounds in the I154F frataxin
point-mutation model, to determine if cells can be rescued from a
lethal or sublethal concentration of FAC and/or BSO. [0271] 3.
Evaluate compounds in the I154F frataxin point-mutation model, to
determine if mitochondrial function can be improved, or if
mitochondrial iron or oxidative stress can be decreased, or if any
other phenotype associated with decreased or impaired frataxin
function can be partially or fully reversed. [0272] 4. Evaluate the
catalytic activity of the compound by pre-loading with manganese or
iron or other metal and assaying superoxide dismutase or catalase
activity in vitro.
[0273] As a result, a probe or therapeutic compound is identified
that acts upon a specific ETC complex. Each of the foregoing steps
is described in more detail below. While the screening in the order
mentioned below and including all of the steps is typically
performed, it is not necessary to do so and active compounds can be
identified using a subset of the assays mentioned, from one assay
to any combination of any number of assays, in any order.
[0274] Step 1. Primary Screening. The primary yeast screen is
described above and in Examples 1 and 2 below.
[0275] Step 2. Secondary Screening. The secondary screen employs
mammalian (C2C12) cells treated with ferric ammonium citrate (FAC)
and/or L-buthionine (S,R)-sulfoximine (BSO), using ATP
measurements. Approximately 4000 cells per well were plated in
standard medium in 96-well plates and FAC was added 4 hours later.
The cells were incubated overnight (20 h) in standard
tissue-culture incubators, after which BSO was added. After another
overnight incubation (24 h) ATP content was determined using the
CellTiter-Glo assay. The synergistic effects of FAC and BSO
presumably derived from the combination of increased oxidative
stress (secondary to the FAC) with decreased cellular antioxidant
capacity (secondary to the BSO).
[0276] Step 3. Screening in yeast lacking functional complex V. The
effects of several compounds on ATP content in yeast (using the
CellTiter-Glo assay) with and without ATP15p, which is required for
the function of complex V. Active compounds generally increase ATP
dramatically within minutes; the differences from carrier controls
diminish with time and equalize over the course of days. These
results suggest a pent-up demand for ATP, a burst of new synthesis,
and a gradual return to equilibrium levels, which are normally
maintained within a fairly narrow range by feedback mechanisms.
Compounds that depend on complex V for at least 50% of their
activity are carried through to step 4.
[0277] Step 4. Screening in yeast lacking functional mitochondrial
complexes I, II, III, and IV. Relative to carrier controls,
treatment of cells completely lacking Ndi1 (which encodes the yeast
equivalent of complex I) with active compounds can induce an
increase of ATP of up to 25-fold or more within minutes. The
differences from carrier controls diminish with time and equalize
over the course of days, suggesting a pent-up demand for ATP, a
burst of new synthesis, and a gradual return to equilibrium
levels.
[0278] Step 5. Screening in mammalian cells treated with inhibitors
of specific complexes of the ETC. Rotenone, antimycin A, and
oligomycin have been used in experiments with primary FRDA
fibroblasts to show that rotenone inhibits complex I in SH-SY5Y
cells in the nM range, and kills SH-SY5Y cells in the .mu.M range
(with 90% death, as assessed by trypan blue exclusion, after 7 days
at 60 .mu.M). Antimycin A and oligomycin kill SH-SY5Y cells in the
high nM range, as assessed by LDH leakage and DNA
fragmentation.
[0279] The additional screens are described in more detail
below.
[0280] 1. This assay is employed to determine whether test compound
can rescue HepG2 cells from lethal concentrations of FAC+BSO. In
addition to the C2C12 assay described herein, the human
hepatocellular carcinoma line HepG2, is treated with ferric
ammonium citrate (FAC) and/or L-buthionine (S,R)-sulfoximine (BSO),
which inhibits the rate-limiting step of glutathione synthesis. A
finding of a low effective concentration can support a mechanism
other than iron chelation, such as a catalytic mechanism, such as
mimicking SOD and/or catalase.
[0281] 2. Preliminary testing in the I154F frataxin point-mutation
model determines whether test compounds can rescue I154F FA cells
from lethal concentrations of FAC and/or BSO. Among the
mammalian-cell models that have, or recapitulate, the genetic
defects underlying FA, by far the most robust (and best validated)
is the I154F murine frataxin point-mutation model developed by
Puccio and colleagues (Calmels, N. et al.), the first cellular
model based on frataxin missense mutations that reproduces
spontaneously the defects associated with Friedreich ataxia (PLoS
One 4, e6379 (2009)). This model exhibits all the hallmarks of FA,
including mitochondrial iron accumulation, loss of
iron-sulfur-cluster-enzyme activities, and sensitivity to iron and
oxidative stress. This model is also extremely stable, with
phenotypes unchanged after months of continuous culture. In
contrast, the mutations in available primary human FA fibroblasts
are GAA repeat expansions in the first intron of the FXN gene;
occasional cells in which these expansions contract have a growth
advantage and take over the culture, diluting the phenotype and
increasing variance in various measures of compound efficacy. Also
in contrast, the RNAi models tend to have weak phenotypes and, like
the human FA Fibroblasts, to exhibit a high variability in
culture.
[0282] 3. Evaluate the catalytic activity of the compound by
pre-loading with manganese, iron, or other metal and assaying
superoxide dismutase and/or catalase activity in vitro. This assay
helps identify a possible mechanism of action that would help
explain the unusual combination of high potency, and high
specificity, of the compounds embodied herein. A picomolar potency
in cell-based assays can suggest that compounds are acting
catalytically. Yet compounds that act catalytically are usually
relatively non-specific, whereas the compounds embodied herein were
confirmed active in only one assay (the FA yeast assay mentioned
above) of 168 high-throughput screening assays in which they have
been tested to date. With no duty to disclose the mechanism of
action of the compounds embodied here and without being bound based
thereon, it is hypothesized that the compounds embodied herein are
chelating iron within cells and acting as superoxide dismutase
(SOD) and/or catalase mimetics.
[0283] As will be seen in the examples below, compounds embodied
herein display a high level of potency, with significant activity
in the picomolar range in mammalian cells, and high specificity.
Based on the results of the screening, and preliminary testing,
compounds embodied herein are hypothesized to become activated to
mimic superoxidase and/or catalase activity only in cells
containing excess levels of labile iron. Because diseases described
herein such as Friedreich's ataxia have pathophysiological
mechanisms arising from increased intracellular iron, such
compounds are particularly suitable for their prophylaxis or
treatment, and also such a mechanism can offer benefit in other
diseases in which iron accumulation and attendant oxidative stress
contribute to the pathophysiology. Thus, in another embodiment, a
compounds and methods are provided for decreasing intracellular
iron by exposing the cells to a compound described herein. In
another embodiment, a compounds and methods are provided for
decreasing intramitochondrial iron by exposing the cells to a
compound described herein. In another embodiment, compounds and
methods are provided for decreasing intracellular and/or
intramitochondrial oxidative stress by exposing the cells to a
compound described herein. In another embodiment, compounds and
methods are provided for decreasing mitochondrial dysfunction by
exposing the cells to a compound described herein.
[0284] In another embodiment, a method is provided for identifying
cells, tissues, or cells or tissues from a subject that may have a
defect in mitochondrial function, cellular respiration upstream
from or regulated by frataxin activity or the phenotype thereof.
Such cells might be from a patient or subject with a predisposition
to a disease such as any of those mentioned herein. In the practice
of the method, the effect on mitochondrial function or cellular
respiration in the cells or tissues by a compound of formula (I) or
a pharmaceutical composition thereof is performed, following the
teachings herein. If a compounds of the invention is found to
improve mitochondrial function or cellular respiration, this result
provides evidence that the cells or tissues as have a defect in
mitochondrial function or cellular respiration. The patient or
subject may be started on therapy to treat or prophylaxe the
disease, such as by treatment with a compound described herein.
[0285] In another embodiment, the compound of formula (I) for the
aforementioned method can have a structure of formula (II) or (III)
or any of the compounds described hereinabove.
[0286] In another embodiment, the compounds described herein are
activated by binding to a metal ion such as iron (II) or iron
(III), or in other embodiments, manganese ion, such as Mn (II),
(III), (IV), (VI) or (VII). Other metal cations are encompassed
herein. Studies described herein suggest that the compounds
embodied here are precursors of the active form of the molecule
that reduces oxidative stress, decreases mitochondrial iron
accumulation, and improves the cellular metabolism of cells with
iron accumulation. In another embodiment, the compounds embodied
herein become activated to catalyze the degradation of superoxide
or hydrogen peroxide. As such, compounds described herein may be
considered active form precursors of superoxide dismutase or
catalase. While Applicants have no duty to disclose the mechanism
by which the compounds operate and are not restricted thereto, the
mechanism for the biological activity of the compounds provide a
rationale for their high specificity and potency.
Compounds, Pharmaceutical Compositions and Methods of
Administration
[0287] Another embodiment herein comprises compounds and
pharmaceutical compositions of such compounds useful for the
purposes described herein, but not limited thereto, that have the
structure of formula (I):
##STR00021## [0288] wherein A is an optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0289] R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0290] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0291] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; and [0292] R.sup.4 and R.sup.6 are
each independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl; and
[0293] R.sup.7 is hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with a
halogen, a --C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0294] or an isomer, stereoisomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0295] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy. In other embodiments, A is
a substituted aryl group or an optionally substituted furyl group.
In further embodiments, R.sup.3 is an optionally substituted alkyl
or aralkyl group. Non-limiting examples of aralkyl include phenyl,
benzyl, phenylethyl, phenylpropyl, phenylbutyl and phenylpentyl.
The foregoing aralkyl groups may be substituted on the aryl moiety,
or on the alkyl moiety, or both. Non-limiting examples of alkyl
include methyl, ethyl, n-propyl, 2-propyl, n-butyl, t-butyl,
n-pentyl and n-hexyl. By way of non-limiting example, moiety A can
be a substituted or unsubstituted heteroaryl group such as a
thienyl, pyrrolyl or furyl group. In certain embodiments A is
2-thienyl. In other embodiments, A is a substituted or
unsubstituted aryl group. In other embodiments A is phenyl. In
other embodiments A is a heterocyclic group. In other embodiments A
is substituted with one or more alkyl, alkoxy or halo groups, such
as but not limited to methyl, methoxy or chloro. In certain
embodiments A is 4-methylphenyl, 2-methoxyphenyl, or
3,4-dimethoxyphenyl.
[0296] In certain embodiments, the compound of formula (I) has the
structure of formula (II):
##STR00022## [0297] wherein B is O, N or S; [0298] R.sup.1 is
hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro, NH.sub.2,
NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, or an
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic; [0299] R.sup.2 is --OR,
wherein R is --C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0300] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0301] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0302] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0303] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0304] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0305] In certain embodiments, B is O. In other embodiments B is S.
In further embodiments. R.sup.1 can be hydroxy, nitro or halogen.
In other embodiments R.sup.2 can be hydroxy or methoxy. In other
embodiments, R.sup.3 can be alkyl or aralkyl. In other embodiments
R.sup.5 is one or more alkyl, alkoxy or halo groups, such as but
not limited to methyl, methoxy or chloro. Non-limiting examples of
aralkyl include phenyl, benzyl and phenylethyl. The foregoing
aralkyl groups may be substituted on the aryl moiety, or on the
alkyl moiety, or both. Non-limiting examples of alkyl include
methyl, ethyl, n-propyl, 2-propyl, n-butyl, t-butyl, n-pentyl and
n-hexyl.
[0306] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-2-methylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]acetamide,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide.
[0307] In certain other embodiments, compound (1) has the structure
of formula (III)
##STR00023## [0308] wherein R.sup.1 is hydrogen, hydroxy, halogen,
cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, or an optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; [0309] R.sup.2 is --OR, wherein R is
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --SO.sub.2NR.sup.4R.sup.6,
--SO.sub.2R.sup.7, --COR.sup.7, --COOR.sup.7 or
--CONR.sup.4R.sup.6, wherein (a) one or more of the carbon atoms in
the alkyl, alkenyl or alkynyl group is each independently
optionally replaced with a nitrogen, sulfur or oxygen atom, and (b)
the alkyl, alkenyl or alkynyl group is optionally substituted with
a --C.sub.1-C.sub.3-alkyl; [0310] R.sup.3 is an optionally
substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic, or heteroaromatic; [0311] R.sup.4 and R.sup.6 are each
independently hydrogen, --C.sub.1-C.sub.6-alkyl,
--C.sub.2-C.sub.6-alkenyl, --C.sub.2-C.sub.6-alkynyl, --COR.sup.7,
--C.sub.5-C.sub.7-aryl, or --C.sub.5-C.sub.10-arylalkyl, wherein
(a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl,
aryl or arylalkyl group is each independently optionally replaced
with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl,
alkynyl, aryl or arylalkyl is optionally substituted with an
oxygen, a --C.sub.1-C.sub.3-alkyl, or a --C.sub.5-C.sub.7-aryl;
[0312] R.sup.5 is one or more hydrogen, hydroxy, halogen, cyano,
alkyloxy, nitro, NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4,
CONHR.sup.4, COOR.sup.4, optionally substituted aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic; and [0313] R.sup.7 is hydrogen,
--C.sub.1-C.sub.6-alkyl, --C.sub.2-C.sub.6-alkenyl,
--C.sub.2-C.sub.6-alkynyl, --C.sub.5-C.sub.7-aryl, or
--C.sub.5-C.sub.10-arylalkyl, wherein (a) one or more of the carbon
atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is
each independently optionally replaced with a nitrogen, sulfur or
oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl
is optionally substituted with a halogen, a
--C.sub.1-C.sub.3-alkyl, a --C.sub.5-C.sub.7-aryl, or
--NR.sup.4R.sup.6 or --OR.sup.4; [0314] or an isomer, enantiomer,
racemate, prodrug, active metabolite, metal chelate, or a
pharmaceutically-acceptable derivative or salt form of any of the
foregoing.
[0315] In certain embodiments, R.sup.1 is chloro, nitro or cyano.
In other embodiments R.sup.2 is hydroxy or methoxy. In other
embodiments, R.sup.3 can be alkyl or aralkyl. In other embodiments
R.sup.J is alkyl or aralkyl. Non-limiting examples of aralkyl
include phenyl, benzyl and phenylethyl. The foregoing aralkyl
groups may be substituted on the aryl moiety, or on the alkyl
moiety, or both. Non-limiting examples of alkyl include methyl,
ethyl, n-propyl, 2-propyl, n-butyl, t-butyl, n-pentyl and n-hexyl.
In other embodiments, R.sup.5 can be one or more alkyl, alkoxy,
halo or dimethylamino groups.
[0316] In certain embodiments, R.sup.1 is chloro and R.sup.2 is
hydroxy. In other embodiments, R.sup.5 is one or more methoxy,
hydroxy, halo, or dimethylamino groups.
[0317] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanam-
ide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamid-
e,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
and
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide.
[0318] Moreover, any compound of formula (I), (II) or (III) can be
present as a metal chelate, such that embodied herein are the
isolated compounds mentioned above to which one or more metal ions
are bound, such as but not limited to iron (II), iron (III), Mn
(II), Mn (III), Mn (IV), Mn (VI) or Mn (VII), or a compound of
formula (I), (II) or (III) that has entered a biological system
such as a tissue, cell, or subcellular compartment such as but not
limited to a mitochondrion, and therein binds to one or more free
metal ions present therein, and has become activated to carry out
the various beneficial functions mentioned herein throughout. As
noted above, the compounds, in one embodiment, are active in cells
that have elevated levels of intracellular iron, which in itself is
pathologic or portends adverse cellular physiology; binding to the
compound of the invention reduces the excess intracellular iron
level and/or activates the catalytic activity of the compound,
reducing levels of oxidants, decreasing oxidant stress and reducing
pathology. Mechanisms including binding to intracellular metal
ions, which reduces the ability of such ions to participate in the
generation of reactive oxygen species, and/or catalytic activity to
degrade reactive oxygen species such as superoxides and peroxides,
are potential mechanisms benefitting the treatment of diseases of
dysrupted iron metabolism. As noted above, Applicants are not bound
to the mechanism described herein.
[0319] A number of important subclasses of the structure of formula
(I) deserves separate mention; these include subclasses in which:
[0320] i) R.sup.1 is hydrogen, hydroxy, halogen, cyano, nitro,
NH.sub.2 or is alkyloxy, [0321] ii) R.sup.2 is hydroxy or alkoxy,
[0322] iii) R.sup.3 is an optionally substituted aralkyl group,
[0323] iv) A is a heterocyclic group, [0324] v) A is a heteroaryl
group, [0325] vi) A is an aryl group, and/or [0326] vii) A is a
substituted aryl group.
[0327] In certain embodiments, R.sup.1 is a halogen. In certain
embodiments, R.sup.1 is chloro. In certain embodiments, R.sup.2 is
hydroxy. In certain embodiments, R.sup.3 is phenyl. In certain
embodiments. R.sup.3 is benzyl. In certain embodiments, R.sup.3 is
phenylethyl. In certain embodiments, R.sup.3 is phenylpropyl. In
certain embodiments, R.sup.3 is phenylbutyl. In certain
embodiments. R.sup.3 is phenylpentyl. In certain embodiments, A is
furyl. In certain embodiments A is a substituted phenyl group.
[0328] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylp-
ropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)methyl]-3-phe-
nylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide.
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide, and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide.
[0329] A number of important subclasses of the structure of formula
(II) deserves separate mention; these include subclasses in which:
[0330] i) R.sup.1 is hydrogen, hydroxy, halogen, cyano, nitro,
NH.sub.2 or is alkyloxy, [0331] ii) R.sup.2 is hydroxy or alkoxy,
[0332] iii) R.sup.3 is an optionally substituted aralkyl group,
[0333] iv) B is oxygen, [0334] v) B is sulfur, [0335] vi) B is
nitrogen and/or [0336] vii) R.sup.5 one or more hydrogen, hydroxy,
halogen, cyano, alkyloxy, nitro, NH.sub.2, NHCOR.sup.4,
NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4, optionally substituted
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or
heteroaromatic, where R.sup.4 is as defined in formula (II)
above.
[0337] In certain embodiments, R.sup.1 is a halogen. In certain
embodiments, R.sup.1 is chloro. In certain embodiments, R.sup.2 is
hydroxy. In certain embodiments, R.sup.3 is phenyl. In certain
embodiments, R.sup.3 is benzyl. In certain embodiments, R.sup.3 is
phenylethyl. In certain embodiments, R.sup.3 is phenylpropyl. In
certain embodiments, R.sup.3 is phenylbutyl. In certain
embodiments, R.sup.3 is phenylpentyl. In certain embodiments, B is
oxygen.
[0338] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanamid-
e.
[0339] A number of important subclasses of the structure of formula
(III) deserves separate mention; these subclasses include
subclasses of the foregoing classes in which: [0340] i) R.sup.1 is
hydrogen, hydroxy, halogen, cyano, nitro, NH.sub.2 or is alkyloxy,
[0341] ii) R.sup.2 is hydroxy or alkoxy, [0342] iii) R.sup.3 is an
optionally substituted aralkyl group, and/or [0343] iv) R.sup.5 one
or more hydrogen, hydroxy, halogen, cyano, alkyloxy, nitro,
NH.sub.2, NHCOR.sup.4, NHSO.sub.2R.sup.4, CONHR.sup.4, COOR.sup.4,
optionally substituted aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic, or heteroaromatic, where R.sup.4 is
described in formula (III) above.
[0344] In certain embodiments, R.sup.1 is a halogen. In certain
embodiments, R.sup.1 is chloro. In certain embodiments, R.sup.2 is
hydroxy. In certain embodiments, R.sup.3 is phenyl. In certain
embodiments. R.sup.3 is benzyl. In certain embodiments, R.sup.3 is
phenylethyl. In certain embodiments, R.sup.3 is phenylpropyl. In
certain embodiments, R.sup.3 is phenylbutyl. In certain
embodiments, R.sup.3 is phenylpentyl. In certain embodiments,
R.sup.5 is other than hydrogen. In certain embodiments, R.sup.5 is
one or more alkoxy, halo, dimethylamino, or alkyl groups.
[0345] Non-limiting examples of such compounds include
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide, and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide.
[0346] Pharmaceutical compositions comprising any of the
aforementioned compounds and classes and subclasses of special
interest are embraced herein.
[0347] Embodied herein are compounds as described above and
pharmaceutical compositions thereof. It will be appreciated that
the compounds and compositions, according to the methods of the
present invention, may be administered using any amount and any
route of administration effective for the treatment of conditions
or diseases in which increasing mitochondrial activity, decreasing
intracellular and/or intramitochondrial iron, and/or decreasing
intracellular and/or intramitochondrial oxidative stress has a
therapeutically useful role. Thus, the expression "effective
amount" as used herein, refers to a sufficient amount of agent to
modulate mitochondrial activity, intracellular and/or
intramitochondrial iron, and/or intracellular and/or
intramitochondrial oxidative stress, and to exhibit a therapeutic
effect. The exact amount required will vary from subject to
subject, depending on the species, age, and general condition of
the subject, the particular therapeutic agent, its mode and/or
route of administration, and the like. The compounds of the
invention are preferably formulated in dosage unit form for ease of
administration and uniformity of dosage. The expression "dosage
unit form" as used herein refers to a physically discrete unit of
therapeutic agent appropriate for the patient to be treated. It
will be understood, however, that the total daily usage of the
compounds and compositions of the present invention will be decided
by the attending physician within the scope of sound medical
judgment. The specific therapeutically effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex and diet of the patient; the lime of administration,
route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound employed;
and like factors well known in the medical arts.
[0348] Furthermore, after formulation with an appropriate
pharmaceutically acceptable carrier in a desired dosage, the
pharmaceutical compositions of this invention can be administered
to humans and other animals orally, rectally, parenterally,
intracistemally, intravaginally, intraperitoneally, subcutaneously,
intradermally, intra-ocularly, topically (as by powders, ointments,
or drops), buccally, as an oral or nasal spray, or the like,
depending on the severity of the disease or disorder being treated.
In certain embodiments, the compounds of the invention may be
administered at dosage levels of about 0.001 mg/kg to about 50
mg/kg, preferably from about 0.1 mg/kg to about 10 mg/kg for
parenteral administration, or preferably from about 1 mg/kg to
about 50 mg/kg, more preferably from about 10 mg/kg to about 50
mg/kg for oral administration, of subject body weight per day, one
or more times a day, to obtain the desired therapeutic effect. It
will also be appreciated that dosages smaller than 0.001 mg/kg or
greater than 50 mg/kg (for example 50-100 mg/kg) can be
administered to a subject. In certain embodiments, compounds are
administered orally or parenterally.
[0349] In another embodiment of methods and compositions of the
present invention, the pharmaceutical compositions are administered
orally, and are thus formulated in a form suitable for oral
administration, i.e. as a solid or a liquid preparation. Suitable
solid oral formulations include tablets, capsules, pills, granules,
pellets and the like. Suitable liquid oral formulations include
solutions, suspensions, dispersions, emulsions, oils and the like.
In another embodiment of the present invention, the active
ingredient is formulated in a capsule. In accordance with this
embodiment the compositions of the present invention comprise, in
addition to the active compound and the inert carrier or diluent, a
hard gelatin capsule.
[0350] In another embodiment, the pharmaceutical compositions are
administered by intravenous, intra-arterial, subcutaneous or
intra-muscular injection of a liquid preparation. Suitable liquid
formulations include solutions, suspensions, dispersions,
emulsions, oils and the like. In another embodiment, the
pharmaceutical compositions are administered intravenously and are
thus formulated in a form suitable for intravenous administration.
In another embodiment, the pharmaceutical compositions are
administered intra-arterially and are thus formulated in a form
suitable for intra-arterial administration. In another embodiment,
the pharmaceutical compositions are administered intra-muscularly
and are thus formulated in a form suitable for intra-muscular
administration.
[0351] In another embodiment, the pharmaceutical compositions are
administered topically to body surfaces and are thus formulated in
a form suitable for topical administration. Topical formulations
include, in another embodiment, gels, ointments, creams, lotions,
drops and the like.
[0352] In another embodiment, the pharmaceutical composition is
administered as a suppository, for example a rectal suppository or
a urethral suppository. In another embodiment, the pharmaceutical
composition is administered by subcutaneous implantation of a
pellet. In another embodiment, the pellet provides for controlled
release of active agent over a period of time.
[0353] In another embodiment, the active compound is delivered in a
vesicle, e.g. a liposome.
[0354] In other embodiments, carriers or diluents used in methods
of the present invention include, but are not limited to, a gum, a
starch (e.g. corn starch, prcgeletanized starch), a sugar (e.g.,
lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g.
microcrystalline cellulose), an acrylate (e.g. polymelhylacrylate),
calcium carbonate, magnesium oxide, talc, or mixtures thereof.
[0355] In other embodiments, pharmaceutically acceptable carriers
for liquid formulations are aqueous or non-aqueous solutions,
suspensions, emulsions or oils. Examples of non-aqueous solvents
are propylene glycol, polyethylene glycol, and injectable organic
esters such as ethyl oleate. Aqueous carriers include water,
alcoholic/aqueous solutions, emulsions or suspensions, including
saline and buffered media. Examples of oils are those of animal,
vegetable, or synthetic origin, for example, peanut oil, soybean
oil, olive oil, sunflower oil, fish-liver oil, another marine oil,
or a lipid from milk or eggs.
[0356] In another embodiment, parenteral vehicles (for
subcutaneous, intravenous, intra-arterial, or intramuscular
injection) include sodium chloride solution, Ringer's dextrose,
dextrose and sodium chloride, lactated Ringer's and fixed oils.
Intravenous vehicles include fluid and nutrient replenishes,
electrolyte replenishes such as those based on Ringer's dextrose,
and the like. Examples are sterile liquids such as water and oils,
with or without the addition of a surfactant and other
pharmaceutically acceptable adjuvants. In general, water, saline,
aqueous dextrose and related sugar solutions, and glycols such as
propylene glycols or polyethylene glycol are preferred liquid
carries, particularly for injectable solutions. Examples of oils
are those of animal, vegetable, or synthetic origin, for example,
peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil,
another marine oil, or a lipid from milk or eggs.
[0357] In other embodiments, the compositions further comprise
binders (e.g. acacia, cornstarch, gelatin, carbomer, ethyl
cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl
cellulose, povidone), disintegrating agents (e.g. cornstarch,
potato starch, alginic acid, silicon dioxide, croscarmelose sodium,
crospovidone, guar gum, sodium starch glycolate), buffers (e.g.,
Tris-HCl, acetate, phosphate) of various pH and ionic strength,
additives such as albumin or gelatin to prevent absorption to
surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile
acid salts), protease inhibitors, surfactants (e.g. sodium lauryl
sulfate), permeation enhancers, solubilizing agents (e.g.,
glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic
acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers
(e.g. hydroxypropyl cellulose, hyroxypropylmethyl cellulose),
viscosity increasing agents (e.g. carbomer, colloidal silicon
dioxide, ethyl cellulose, guar gum), sweeteners (e.g. aspartame,
citric acid), preservatives (e.g., Thimerosal, benzyl alcohol,
parabens), lubricants (e.g. stearic acid, magnesium stearate,
polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g.
colloidal silicon dioxide), plasticizers (e.g. diethyl phthalate,
triethyl citrate), emulsifiers (e.g. carbomer, hydroxypropyl
cellulose, sodium lauryl sulfate), polymer coatings (e.g.,
poloxamers or poloxamines), coating and film forming agents (e.g.
ethyl cellulose, acrylates, polymethacrylates) and/or adjuvants.
Each of the above excipients represents a separate embodiment of
the present invention.
[0358] In another embodiment, the pharmaceutical compositions
provided herein are controlled-release compositions, i.e.
compositions in which the active compound is released over a period
of time after administration. Controlled- or sustained-release
compositions include formulation in lipophilic depots (e.g. fatty
acids, waxes, oils). In another embodiment, the composition is an
immediate-release composition, i.e. a composition in which of the
active compound is released immediately after administration.
[0359] In another embodiment, the pharmaceutical composition is
delivered in a controlled release system. For example, the agent
may be administered using intravenous infusion, an implantable
osmotic pump, a transdermal patch, liposomes, or other modes of
administration. In one embodiment, a pump may be used (see Langer,
supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald
et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med.
321:574 (1989). In another embodiment, polymeric materials are
used; e.g. in microspheres in or an implant. In yet another
embodiment a controlled release system is placed in proximity to
the target cell, thus requiring only a fraction of the systemic
dose (see, e.g., Goodson, in Medical Applications of Controlled
Release, supra, vol. 2, pp. 115-138 (1984); and Langer R, Science
249: 1527-1533 (1990).
[0360] The compositions also include, in another embodiment
incorporation of the active material into or onto particulate
preparations of polymeric compounds such as polylactic acid,
polglycolic acid, hydrogels, etc, or onto liposomes,
microemulsions, micelles, unilamellar or multilamellar vesicles,
erythrocyte ghosts, or spheroplasts.) Such compositions will
influence the physical state, solubility, stability, rate of in
vivo release, and rate of in vivo clearance.
[0361] Also included in the present invention are particulate
compositions coated with polymers (e.g. poloxamers or poloxamines)
and the compound coupled to antibodies directed against
tissue-specific receptors, ligands or antigens or coupled to
ligands of tissue-specific receptors.
[0362] Also comprehended by the invention are compounds modified by
the covalent attachment of water-soluble polymers such as
polyethylene glycol, copolymers of polyethylene glycol and
polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl
alcohol, polyvinylpyrrolidone or polyproline. The modified
compounds are known to exhibit substantially longer half-lives in
blood following intravenous injection than do the corresponding
unmodified compounds. Such modifications may also increase the
compound's solubility in aqueous solution, eliminate aggregation,
enhance the physical and chemical stability of the compound, and
greatly reduce the immunogenicity and reactivity of the compound.
As a result, the desired in vivo biological activity may be
achieved by the administration of such polymer-compound abducts
less frequently or in lower doses than with the unmodified
compound.
[0363] Each of the above additives, excipients, formulations and
methods of administration represents a separate embodiment of the
present invention.
[0364] In one embodiment, the methods of the present invention
comprise administering an active compound as the sole active
ingredient. However, also encompassed within the scope of the
present invention are methods for treating diseases and disorders
that comprise administering the active compound in combination with
one or more therapeutic agents. In another embodiment, these agents
are appropriate for the disease or disorder that is being treated,
as is well known in the art.
[0365] In one embodiment, the methods of the present invention
comprise administering an active compound as the sole active
ingredient. However, also encompassed within the scope of the
present invention are methods for treating diseases and disorders
that comprise administering the active compound in combination with
one or more therapeutic agents. In another embodiment, these agents
are appropriate for the disease or disorder that is being treated,
as is well known in the art.
[0366] Some of the foregoing compounds can comprise one or more
asymmetric centers, and thus can exist in various isomeric forms,
e.g., stereoisomers and/or diastereomers. Thus, inventive compounds
and pharmaceutical compositions thereof may be in the form of an
individual enantiomer, diastereomer or geometric isomer, or may be
in the form of a mixture of stereoisomers. In certain embodiments,
the compounds of the invention are enantiopure compounds. In
certain other embodiments, mixtures of stereoisomers or
diastereomers are provided. In other embodiments, racemic mixtures
are provided.
[0367] Furthermore, certain compounds, as described herein may have
one or more double bonds that can exist as either the Z or E
isomer, unless otherwise indicated. The invention additionally
encompasses the compounds as individual isomers substantially free
of other isomers and alternatively, as mixtures of various isomers,
e.g., racemic mixtures of stereoisomers. In addition to the
above-mentioned compounds per se, this invention also encompasses
pharmaceutically acceptable derivatives of these compounds and
compositions comprising one or more compounds of the invention and
one or more pharmaceutically acceptable excipients or
additives.
[0368] The foregoing description is illustrated by the following
non-limiting examples.
EXAMPLES
Example 1
Preparation of Compounds of the Invention
[0369] The practitioner has a well-established literature of small
molecule chemistry to draw upon, in combination with the
information contained herein, for guidance on synthetic strategies,
protecting groups, and other materials and methods useful for the
synthesis of the compounds of this invention.
[0370] The various references cited herein provide helpful
background information on preparing compounds similar to the
inventive compounds described herein or relevant intermediates, as
well as information on formulation, uses, and administration of
such compounds which may be of interest.
[0371] Moreover, the practitioner is directed to the specific
guidance and examples provided in this document relating to various
exemplary compounds and intermediates thereof.
[0372] The compounds of this invention and their preparation can be
understood further by the examples that illustrate some of the
processes by which these compounds are prepared or used. It will be
appreciated, however, that these examples do not limit the
invention. Variations of the invention, now known or further
developed, are considered to fall within the scope of the present
invention as described herein and as hereinafter claimed.
[0373] According to the present invention, any available techniques
can be used to make or prepare the inventive compounds or
compositions including them. For example, a variety of solution
phase synthetic methods such as those discussed in detail below may
be used. Alternatively or additionally, the inventive compounds may
be prepared using any of a variety combinatorial techniques,
parallel synthesis and/or solid phase synthetic methods known in
the art.
[0374] It will be appreciated as described below, that a variety of
inventive compounds can be synthesized according to the methods
described herein. The starting materials and reagents used in
preparing these compounds are either available from commercial
suppliers such as Aldrich Chemical Company (Milwaukee, Wis.),
Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or are prepared
by methods well known to a person of ordinary skill in the art
following procedures described in such references as Fieser and
Fieser 1991, "Reagents for Organic Synthesis", vols 1-17, John
Wiley and Sons, New York, N.Y., 1991; Rodd 1989 "Chemistry of
Carbon Compounds", vols. 1-5 and supps, Elsevier Science
Publishers, 1989; "Organic Reactions", vols 1-40, John Wiley and
Sons, New York, N.Y., 1991; March 2001, "Advanced Organic
Chemistry", 5th ed. John Wiley and Sons, New York, N.Y.; and Larock
1990, "Comprehensive Organic Transformations: A Guide to Functional
Group Preparations", 2nd ed. VCH Publishers. These schemes are
merely illustrative of some methods by which the compounds of this
invention can be synthesized, and various modifications to these
schemes can be made and will be suggested to a person of ordinary
skill in the art having regard to this disclosure.
[0375] The starting materials, intermediates, and compounds of this
invention may be isolated and purified using conventional
techniques, including filtration, distillation, crystallization,
chromatography, and the like. They may be characterized using
conventional methods, including physical constants and spectral
data.
General Reaction Procedures:
[0376] Unless mentioned specifically, reaction mixtures are stirred
using a magnetically driven stirrer bar. An inert atmosphere refers
to either dry argon or dry nitrogen. Reactions are monitored either
by thin layer chromatography, by proton nuclear magnetic resonance
(NMR) or by high-pressure liquid chromatography (HPLC), of a
suitably worked up sample of the reaction mixture.
General Work Up Procedures:
[0377] Unless mentioned specifically, reaction mixtures are cooled
to room temperature or below then quenched, when necessary, with
either water or a saturated aqueous solution of ammonium chloride.
Desired products are extracted by partitioning between water and a
suitable water-immiscible solvent (e.g. ethyl acetate,
dichloromethane, diethyl ether). The desired product containing
extracts are washed appropriately with water followed by a
saturated solution of brine. On occasions where the product
containing extract is deemed to contain residual oxidants, the
extract is washed with a 10% solution of sodium sulphite in
saturated aqueous sodium bicarbonate solution, prior to the
aforementioned washing procedure. On occasions where the product
containing extract is deemed to contain residual acids, the extract
is washed with saturated aqueous sodium bicarbonate solution, prior
to the aforementioned washing procedure (except in those cases
where the desired product itself had acidic character). On
occasions where the product containing extract is deemed to contain
residual bases, the extract is washed with 10% aqueous citric acid
solution, prior to the aforementioned washing procedure (except in
those cases where the desired product itself had basic character).
Post washing, the desired product containing extracts are dried
over anhydrous magnesium sulphate, and then filtered. The crude
products are then isolated by removal of solvent(s) by rotary
evaporation under reduced pressure, at an appropriate temperature
(generally less than 45.degree. C.).
General Purification Procedures:
[0378] Unless mentioned specifically, chromatographic purification
refers to flash column chromatography on silica, using a single
solvent or mixed solvent as eluent Suitably purified desired
product containing elutes are combined and concentrated under
reduced pressure at an appropriate temperature (generally less than
45.degree. C.) to constant mass.
Synthesis of Exemplary Compounds:
[0379] Unless otherwise indicated, starting materials are either
commercially available or readily accessibly through laboratory
synthesis by anyone reasonably familiar with the art. Described
generally below, are procedures and general guidance for the
synthesis of compounds as described generally and in subclasses and
species herein.
[0380] Compounds embodied herein were synthesized as shown in the
scheme below using a route that employs a microwave-assisted,
3-component Mannich-type reaction (Gilbert, A. M. et al.
N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/ami-
no-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg Med
Chem Lett 18, 6454-7 (2008)) with an average yield of 60%. After
work-up, each compound was purified by HPLC to >95% purity
(LC/MS).
##STR00024##
[0381] All compounds were prepared according to the above scheme
following a similar method. To a microwave vial, 0.5 mmol of
hydroxyquinoline, 0.5 mmol aldehyde (where R.sup.1 corresponds to A
in formula (I)) and 0.5 mmol amide (where R.sup.2 corresponds to
R.sup.3 in formula (I)) were added. The vial was then heated to
120.degree. C. for 30 min. The solids were purified by trituration
with 1:1 hexanes:ethyl acetate. The suspension was filtered and the
solids washed 3 times with 1:1 hexanes:ethyl acetate. The solids
were then further purified by preparative HPLC prior to
testing.
[0382] Following the guidance above, the following compounds were
prepared Other compounds were obtained from commercial sources.
TABLE-US-00001 Molecular weight Compound (M + H.sup.+)
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2- 423.0945
ylmethyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2- 359.0976
ylmethyl]pentanamide N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-
407.1169 ylmethyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2- 331.0854
ylmethyl]propanamide N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-
359.1171 ylmethyl]pentanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3- 417.1417
phenylpropanamide N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3- 447.1494
methoxyphenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4- 460.1807
dimethylaminophenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4- 473.0792 (M + Na.sup.+)
chlorophenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3- 451.0992
chlorophenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2- 451.0959
chlorophenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4- 477.1604
dimethoxyphenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4- 477.1588
dimethoxyphenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5- 507.1702
trimethoxyphenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2- 495.0465
bromophenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl- 431.1533
methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2- 433.1299
hydroxyphenyl)methyl]-3-phenylpropanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4- 447.1483
methoxyphenyl)methyl]-3-phenylpropanamide
Example 2
Yeast-Based Screening Assay
[0383] The aim of this assay is to identify compounds that can
improve mitochondrial function in yeast lacking Yfh1p grown in a
non-fermentable growth medium. The yeast Yfh1p expression construct
used in this study has a galactose-inducible, glucose-repressible
promoter driving Yfh1p production. Yfh1p is expressed when yeast
are grown in the presence of galactose and inhibited when they are
grown in the presence of dextrose. Growing the cells in the
presence of dextrose not only turns off the expression of Yfh1p,
but also leads to the depletion of Yfh1p in the cells. Transferring
the Yfh1p-depleted cells into a non-fermentable, glycerol-based
medium dictates that the yeast must use an oxidative pathway.
Adding drugs that can bypass the lack of Yfh1p lead to recovered
mitochondrial (respiratory) function as demonstrated by the
metabolism of the tetrazolium dye, WST-1. WST-1 is a stable
reagent, often used to monitor cell proliferation, that has a good
linear range and shows accelerated color development. Cleavage of
the tetrazolium salt to formazan is accompanied by an increase in
absorbance at 450 nm.
[0384] Compounds in the single dose assay were evaluated on the
basis of Fold Induction compared to yeast only, and those in the
dose response assay on percent activation, i.e. percent induction
of tetrazolium dye reduction in yeast grown in a non-fermentable
growth medium. Percent activation was calculated using the optical
density in control wells with cells treated with positive control
compound (25 uM methyl 4-(1,2,4,5-tetraazin-3-yl) phenyl ether
(MLSMR External ID: MLS000550612; PubChem SID: 14718875)) as full
induction of tetrazolium dye reduction (100% activation), and wells
with cells grown in medium without methyl
4-(1,2,4,5-tetraazin-3-yl) phenyl ether as an indicator of 0%
activation. Library compounds were screened at 50 uM. From the 50
uM single dose assay, 1250 compounds with significant tetrazolium
dye reduction were selected for confirmatory dose response assay.
These compounds were screened in a 10-point dilution series ranging
from 0.01 to 100 uM.
[0385] The following screening protocol was followed. Yeast cells
containing an inducible/repressible promoter for Yfh1p expression
were cultured in induction medium (Yfh1 on) with Galactose as the
carbon source, and then shifted to repression medium (Yfh1 off)
with Dextrose as the carbon source (for 24 hours) to allow Yfh1
protein to decay. The cells were then incubated for 24 h in
respiration-only medium (Yfh1 off) with Glycerol as the carbon
source to allow cells to equilibrate, and then plated in 384 well
plates in respiration-only medium (Yfh1 off) with glycerol as
carbon source, in the presence of Tetrazolium dye (WST-1) for 72
hours.
[0386] Preparation of Assay [0387] 1. Cells were streaked out on a
YPGa1 agar plate and grown inverted for 3 days at 30 C. [0388] 2. A
colony was selected and 10 mL of YPGa1 medium inoculated and grown
over night at 30 C with shaking. [0389] 3. The cells were counted
on a coulter counter, centrifuged at 1400 g for 5 min in dextrose
(CSMM-D) medium, washed twice to remove all galactose, and
resuspended in CSMM-D medium at a cell density of 2 to the power of
5 cells/mL. [0390] 4. Frozen stocks were prepared at this point, in
dextrose medium. For these dextrose stock solutions, enough culture
was grown in dextrose media over night with shaking at 30 C, to get
a cell density of 2 to the power of 7 cells/mL. The cells were
centrifuged at 1400 g for 5 min and the pellet resuspended in
glycerol freezing medium at a cell density of 2 to the power of 8
cells/mL. [0391] 5. The day before the screen, frozen culture was
thawed at room temperature and resuspended in glycerol (CSMM-G)
medium. [0392] 6. The culture was grown over night at 30 C with
shaking and the cells counted and diluted in CSMM-G medium for a
final cell density of 4 to the power of 6 cells/mL. [0393] 7.
Methyl 4-(1,2,4,5-tetraazin-3-yl) phenyl ether (positive control),
CSMM-G medium alone (negative control) and compounds were plated
with DMSO at 200.times. concentration (final concentrations: methyl
4-(1,2,4,5-tetraazin-3-yl) phenyl ether 25 uM, compounds 50 uM,
DMSO 0.5%) in 384-well plates: 125 nL/well. For the dose response
assay, compounds were plated in a 10-point dilution series ranging
from 0.01 to 100 uM, at 1% DMSO. [0394] 8. 10 uL of a mixture of
WST-1 and CSMM-G medium (1 volume WST-1 to 3 volumes CSMM-G medium)
was added to each well, followed by 15 unwell of diluted
yeast/CSMM-G medium. Plates were incubated at 30 C in a humidified
chamber. [0395] 9. After 72 h incubation, plates were shaken for 30
s and OD450 was read in an EnVision (PerkinElmer) multilabel plate
reader.
[0396] Media Preparation. [0397] 1. YPGa1 (1 L): 10 g yeast extract
(BD #212750); 20 g galactose (Sigma #G0750); 20 g agar (BD
#214010); 20 g peptone (BD #211677). Make volume up to 990 mL with
MQ water. Autoclave at 121 C for 15 min. Add 10 mL Pen/Strep
(invitrogen/GIBCO cat #15140-155). [0398] 2. CSMM-D (Complete
Synthetic Minimal Medium-Dextrose) (1 L): 6.7 g yeast nitrogen base
w/o amino acids (sigma #Y0626); 20 g dextrose (Fisher #D 16500).
Make volume up to 950 mL with MQ water. Autoclave at 121 C for 15
min. Add 40 mL Amino Acid Mix. Add 10 mL Pen/Strep
(invitrogen/GIBCO cat #15140-155). [0399] 3. CSMM-G (Complete
Synthetic Minimal Medium-Glycerol) (1 L): 6.7 g yeast nitrogen base
w/o amino acids (sigma #Y0626); 30 mL glycerol (100%) (Sigma
#G7893). Make volume up to 950 mL with MQ water. Autoclave at 121 C
for 15 min. Add 40 mL Amino Acid Mix. Add 10 mL Pen/Strep
(invitrogen/GIBCO cat #15140-155). [0400] 4. Glycerol Freezing
Medium. Sterile CSMM-glycerol medium with additional 12% glycerol.
[0401] 5. Amino Acid Mix (1 L): 2 g alanine, 0.5 g adenine, 2 g,
arginine, 2 g asparagine, 2 g aspartic acid, 2 g cysteine, 2 g
glutamine, 2 g glutamic acid, 2 g glycine, 2 g histidine, 2 g
myo-inositol, 2 g isoleucine, 10 g leucine, 2 g lysine, 2 g
methionine, 2 g phenylalanine. 2 g proline, 2 g serine, 2 g
threonine, 2 g tryptophan, 2 g tyrosine, 2 g uracil and 2 g
valine.
Example 2
Results of Screening
[0402] Single dose assay: An activity threshold of >1.32 fold
increase in absorbance over the cell control was calculated as
greater than three standard deviations from the median compound
Fold Increase. Therefore, compounds that exhibited >1.32 fold
increase in absorbance were selected as candidates for the
follow-up dose response assay.
[0403] The following compounds were active in the screen:
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(8-hydroxy-5-nitroquinolin-7-yl)-thiophen-2-ylmethyl]butanamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-acetamide,
N-[(8-hydroxy-5-nitro-quinolin-7-yl)-thiophen-2-yl-methyl]-propionamide,
N-[2-furyl(8-hydroxy-5-nitro-7-quinolinyl)methyl]butanamide,
N-[(8-Hydroxy-5-nitro-quinolin-7-yl)-p-tolyl-methyl]-propionamide,
N-[{8-hydroxy-5-nitro-7-quinolinyl}(4-methylphenyl)methyl]acetamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]propanam-
ide,
N-[(8-hydroxyquinolin-7-yl)-(2-methoxyphenyl)methyl]pentanamide and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]propanamide.
Example 3
Additional Screening Assays
[0404] One additional screen employs the murine myoblast (C2C12)
cell line treated with ferric ammonium citrate (FAC) and
L-buthionine (S,R)-sulfoximine (BSO), using ATP measurements.
Approximately 4000 cells per well are plated in standard medium in
96-well plates and FAC is added 4 hours later. The cells are
incubated overnight (20 h) in standard tissue-culture incubators,
after which BSO is added. After another overnight incubation (24 h)
ATP content is determined using the CellTiter-Glo assay. The
synergistic effects of FAC and BSO in decreasing viability, as
measured by ATP content, presumably derive from the combination of
increased oxidative stress (secondary to the FAC) with decreased
cellular antioxidant capacity (secondary to the BSO).
[0405] Cells treated with the compounds embodied herein show a
statistically significant improvement in resistance to treatment
with FAC and/or BSO, as indicated by a statistically significant
improvement in ATP content relative to carrier controls.
[0406] A further screening is performed using yeast lacking
functional complex V. The effects of several compounds on ATP
content in yeast (using the CellTiter-Glo assay) with and without
ATP15p, which is required for the function of complex V. Active
compounds generally increase ATP dramatically within minutes; the
differences from carrier controls diminish with time and equalize
over the course of days. These results suggest a pent-up demand for
ATP, a burst of new synthesis, and a gradual return to equilibrium
levels, which are normally maintained within a fairly narrow range
by feedback mechanisms.
[0407] Screening is then conducted using yeast lacking functional
mitochondrial complexes I, II, m, and IV. Relative to carrier
controls, treatment of cells completely lacking Ndi1 (which encodes
the yeast equivalent of complex I) with active compounds can induce
an increase of ATP of up to 25-fold or more within minutes. The
differences from carrier controls diminish with time and equalize
over the course of days, suggesting a pent-up demand for ATP, a
burst of new synthesis, and a gradual return to equilibrium
levels.
[0408] Further screening in mammalian cells treated with inhibitors
of specific complexes of the ETC is conducted. Rotenone, antimycin
A, and oligomycin have been used in experiments with primary FRDA
fibroblasts to show that rotenone inhibits complex I in SH-SY5Y
cells in the nM range, and kills SH-SY5Y cells in the DM range
(with 90% death, as assessed by trypan blue exclusion, after 7 days
at 60 GM). Antimycin A and oligomycin kill SH-SY5Y cells in the
high nM range, as assessed by LDH leakage and DNA
fragmentation.
Example 4
Additional Screens
[0409] In a further screen, the ability of test compounds to rescue
HepG2 cells from lethal concentrations of FAC+BSO was evaluated.
Conditions included 100 ug/mL FAC and 100 uM BSO, incubated with
cells for 48 hours after which viability was determined using the
methods described above.
[0410] The results showed activity of compounds of the invention in
the picomolar range. These results suggest a mechanism of action
other than iron chelation, perhaps a catalytic mechanism, such as
mimicking SOD and/or catalase. Inventive compounds might be acting
as SOD and/or catalase mimetics, perhaps by chelating intracellular
Mn (or even Fe). Supporting this hypothesis are the phenotypic
similarities between yeast lacking Yfh1p and yeast lacking Sod2p.
Activation of the compounds described herein, though the binding of
iron--to become SOD and/or catalase mimetics, or to chelates with
some other beneficial activity--might explain the unusual
combination of high potency and high specificity, since the
compounds would be fully active only in cells with high levels of
free iron.
[0411] In another screen, testing was conducted in the I154F
point-mutation model as described above, to determine whether test
compounds could rescue I154F FA cells from lethal or sublethal
concentrations of FAC and/or BSO. Effective in this screen were the
following compounds:
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]pentanamide-
,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]-3-phenylpropanami-
de,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]propanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-furan-2-ylmethyl]pentanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-tolyl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-methoxyphenyl)methyl]-3-phenylpro-
panamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-dimethylaminophenyl)meth-
yl]-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3-chlorophenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-chlorophenyl)methyl]-3-phenylprop-
anamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4-dimethoxyphenyl)methyl]-
-3-phenylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2,4-dimethoxyphenyl)methyl]-3-pheny-
lpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(3,4,5-trimethoxyphenyl)methyl]-3-ph-
enylpropanamide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-bromophenyl)methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-p-tolyl-methyl]-3-phenylpropa-
namide,
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(2-hydroxyphenyl)methyl]-3-ph-
enylpropanamide (la-18), and
N-[(5-chloro-8-hydroxyquinolin-7-yl)-(4-methoxyphenyl)methyl]-3-phenylpro-
panamide.
[0412] In a further evaluation, the catalytic activity of the test
compound was measured by pre-loading with manganese, or various
forms of iron, or other metals, and assaying superoxide dismutase
activity in vitro using an assay kit from Fluka. Control levels of
inhibition of SOD activity was about 4.5%, and 300 nM compound
N-[(5-chloro-8-hydroxyquinolin-7-yl)-thiophen-2-ylmethyl]-3-phenylpropana-
mide pre-loaded with manganese about 5%. However, preloading with
iron acetate increased inhibition to about 40%. This eight-fold
increase in inhibition by iron suggests that the potency of
compounds of the invention are optimal intracellularly when labile
iron concentrations are at excess and thereby contributory to
pathology through an increase in oxidative stress.
* * * * *
References